###begin article-title 0
###xml 70 73 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Receptor Complementation and Mutagenesis Reveal SR-BI as an Essential HCV Entry Factor and Functionally Imply Its Intra- and Extra-Cellular Domains
###end article-title 0
###begin p 1
These authors contributed equally to this work.
###end p 1
###begin p 2
Conceived and designed the experiments: MD VLDT FLC BB. Performed the experiments: MD VLDT JF MG ZJ GV DD FLC BB. Analyzed the data: MD VLDT JF MG GV FZ DL FLC BB. Contributed reagents/materials/analysis tools: DD FZ DL. Wrote the paper: MD FLC BB.
###end p 2
###begin p 3
###xml 432 435 432 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">via</italic>
###xml 0 3 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 98 101 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 428 431 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 503 506 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 638 641 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 666 669 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1065 1068 <span type="species:ncbi:10116">rat</span>
###xml 1121 1126 <span type="species:ncbi:9606">human</span>
###xml 1150 1153 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1296 1299 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1366 1369 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1484 1487 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1737 1740 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1831 1834 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1896 1899 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
HCV entry into cells is a multi-step and slow process. It is believed that the initial capture of HCV particles by glycosaminoglycans and/or lipoprotein receptors is followed by coordinated interactions with the scavenger receptor class B type I (SR-BI), a major receptor of high-density lipoprotein (HDL), the CD81 tetraspanin, and the tight junction protein Claudin-1, ultimately leading to uptake and cellular penetration of HCV via low-pH endosomes. Several reports have indicated that HDL promotes HCV entry through interaction with SR-BI. This pathway remains largely elusive, although it was shown that HDL neither associates with HCV particles nor modulates HCV binding to SR-BI. In contrast to CD81 and Claudin-1, the importance of SR-BI has only been addressed indirectly because of lack of cells in which functional complementation assays with mutant receptors could be performed. Here we identified for the first time two cell types that supported HCVpp and HCVcc entry upon ectopic SR-BI expression. Remarkably, the undetectable expression of SR-BI in rat hepatoma cells allowed unambiguous investigation of human SR-BI functions during HCV entry. By expressing different SR-BI mutants in either cell line, our results revealed features of SR-BI intracellular domains that influence HCV infectivity without affecting receptor binding and stimulation of HCV entry induced by HDL/SR-BI interaction. Conversely, we identified positions of SR-BI ectodomain that, by altering HCV binding, inhibit entry. Finally, we characterized alternative ectodomain determinants that, by reducing SR-BI cholesterol uptake and efflux functions, abolish HDL-mediated infection-enhancement. Altogether, we demonstrate that SR-BI is an essential HCV entry factor. Moreover, our results highlight specific SR-BI determinants required during HCV entry and physiological lipid transfer functions hijacked by HCV to favor infection.
###end p 3
###begin title 4
Author Summary
###end title 4
###begin p 5
###xml 22 28 <span type="species:ncbi:9606">people</span>
###xml 57 74 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 76 79 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 179 182 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 329 332 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 698 701 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 740 743 <span type="species:ncbi:10116">rat</span>
###xml 889 892 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 973 976 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1035 1038 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
More than 180 million people are chronically infected by hepatitis C virus (HCV), a leading cause of liver failure and cancer, stimulating the need to fully define the biology of HCV infection for developing novel and effective therapeutics. During the first steps of infection, the virus is taken up and penetrates hepatocytes. HCV entry is thought to be a coordinated multi-step process mediated by specific factors, including CD81, Claudin-1, and the scavenger receptor BI (SR-BI). Whereas the involvement of CD81 and Claudin-1 was demonstrated by rendering susceptible cells that are otherwise refractory, SR-BI complementation assays were lacking, raising questions as to its functions during HCV entry. Here, we identify one hepatoma rat cell line, in which SR-BI complementation assay and targeted mutagenesis could be performed. We therefore demonstrate that SR-BI is an essential HCV entry factor. Our results shed light on SR-BI intracellular domain functions in HCV entry, and, further, emphasize the remarkable capacity of HCV to hijack the lipid transfer function of SR-BI, hence favoring infection.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 337 340 337 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Shepard1">[1]</xref>
###xml 529 541 529 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flaviviridae</italic>
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 19 22 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 129 135 <span type="species:ncbi:9606">people</span>
###xml 145 156 <span type="species:ncbi:11103">hepatitis C</span>
###xml 381 392 <span type="species:ncbi:11103">hepatitis C</span>
###xml 443 446 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 475 478 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 722 725 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 846 849 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease world-wide. With 180 million persistently infected people, chronic hepatitis C infection, which induces end-stage liver disease such as liver cirrhosis and hepatocellular carcinoma (HCC), represents a major public health problem of high socio-economic impact [1]. However, treatment options for chronic hepatitis C are limited, and a vaccine for prevention against HCV infection is not available. HCV is a positive strand RNA enveloped virus from the Flaviviridae family. Viral attachment and entry-representing the first encounter of the virus with the host cell-are major targets of adaptive host cell defenses. Detailed understanding of the HCV entry process should offer interesting opportunities for development of novel therapeutic strategies to prevent or cure HCV infection.
###end p 7
###begin p 8
###xml 61 64 61 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch1">[2]</xref>
###xml 65 68 65 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dubuisson1">[3]</xref>
###xml 69 72 69 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-vonHahn1">[4]</xref>
###xml 320 323 320 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Thomssen1">[5]</xref>
###xml 407 410 407 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Agnello1">[6]</xref>
###xml 493 496 493 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Scarselli1">[7]</xref>
###xml 519 522 519 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Pileri1">[8]</xref>
###xml 572 575 572 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Evans1">[9]</xref>
###xml 664 668 664 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Blanchard1">[10]</xref>
###xml 669 673 669 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Meertens1">[11]</xref>
###xml 725 733 725 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 812 816 812 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch2">[12]</xref>
###xml 817 821 817 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Hsu1">[13]</xref>
###xml 822 826 822 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Lavillette1">[14]</xref>
###xml 827 831 827 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Lavillette2">[15]</xref>
###xml 832 836 832 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Tscherne1">[16]</xref>
###xml 881 885 881 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Blanchard1">[10]</xref>
###xml 886 890 886 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Meertens1">[11]</xref>
###xml 903 915 903 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flaviviridae</italic>
###xml 915 919 915 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Kielian1">[17]</xref>
###xml 0 3 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 250 253 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
###xml 629 632 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 758 761 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 985 988 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
HCV entry is thought to be a multi-step process (reviewed in [2],[3],[4]). The interactions between envelope glycoproteins and glycosaminoglycans might contribute to the primary binding of virus particles to host cells. Because of the association of HCV with low-density lipoproteins (LDL) in serum of infected patients [5], the LDL receptor (LDLr) has also been proposed as an alternative capture receptor [6]. Following this initial engagement, the scavenger receptor class B type I (SR-BI) [7], the CD81 tetraspanin [8] and the tight junction protein Claudin-1 (CLDN1) [9] may contribute to uptake and cellular penetration of HCV in a clathrin-dependent manner [10],[11]. Using HCVpp and HCVcc infection assays as well as in vitro membrane fusion assays, HCV entry was shown to occur in a pH-dependent manner [12],[13],[14],[15],[16], through endocytosis of the viral particles [10],[11]. Like other Flaviviridae[17], the low endosomal pH may induce conformational rearrangement of HCV glycoproteins, leading to fusion of the viral membrane with that of the endosome.
###end p 8
###begin p 9
###xml 181 185 181 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Calvo1">[18]</xref>
###xml 289 293 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Webb1">[19]</xref>
###xml 376 380 376 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Krieger1">[20]</xref>
###xml 1042 1046 1042 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Silver1">[21]</xref>
###xml 1175 1179 1175 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Parathath1">[22]</xref>
###xml 1180 1184 1180 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-KellnerWeibel1">[23]</xref>
###xml 66 69 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The exact function of these molecules, and particularly SR-BI, in HCV infection is still enigmatic. SR-BI, also called CLA-1, was originally defined as a class B scavenger receptor [18] in a family that includes CD36, LIMPII and SR-BII, an SR-BI isoform with an alternate cytoplasmic tail [19]. SR-BI mediates binding and lipid transfer from different classes of lipoproteins [20], particularly high-density lipoprotein (HDL), accounting for its multiple functions in cholesterol metabolism such as removal of peripheral unesterified cholesterol, steroidogenesis and bile acid synthesis and secretion. SR-BI stimulates the bi-directional flux of free cholesterol (FC) between cells and lipoproteins, an activity that may be responsible for net cholesterol efflux from peripheral cells as well as the rapid hepatic clearance of FC from plasma HDL. In hepatic cells, SR-BI also mediates the selective uptake of cholesteryl ester (CE) from HDL, a process by which HDL CE is taken into the plasma membrane without degradation of the HDL particle [21]. Through lipid uptake, SR-BI increases cellular cholesterol mass and alters cholesterol distribution in plasma membrane domains [22],[23].
###end p 9
###begin p 10
###xml 33 36 33 36 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Scarselli1">[7]</xref>
###xml 201 205 201 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Maillard1">[24]</xref>
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 309 313 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Catanese1">[26]</xref>
###xml 314 318 314 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux1">[27]</xref>
###xml 319 323 319 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Meunier1">[28]</xref>
###xml 324 328 324 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset1">[29]</xref>
###xml 329 333 329 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset2">[30]</xref>
###xml 482 486 482 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 487 491 487 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset1">[29]</xref>
###xml 733 737 733 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 738 742 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux1">[27]</xref>
###xml 743 747 743 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset1">[29]</xref>
###xml 957 961 957 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 962 966 962 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset1">[29]</xref>
###xml 1337 1340 1337 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Evans1">[9]</xref>
###xml 1341 1345 1341 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch2">[12]</xref>
###xml 1346 1350 1346 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Hsu1">[13]</xref>
###xml 93 96 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 179 182 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 380 383 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 674 677 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 712 715 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 881 884 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1041 1044 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1184 1187 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1297 1300 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1534 1537 <span type="species:ncbi:10116">rat</span>
###xml 1542 1547 <span type="species:ncbi:9606">human</span>
###xml 1582 1585 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1801 1804 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
SR-BI mediates binding of the E2 [7], one of the two glycoproteins exposed at the surface of HCV particles, and, as a multiligand lipoprotein receptor, can also induce binding of HCV associated to LDL [24]. Intriguingly, we, and others, have demonstrated that HDL enhances infectivity of HCVpp and HCVcc [25],[26],[27],[28],[29],[30]. This original mechanism is controlled by the HCV glycoproteins, and, more particularly, by conserved residues of the hypervariable region-1 (HVR1) [25],[29], a 27 amino-acid peptide located at the amino-terminus of E2. HDL-mediated enhancement of infection clearly involves SR-BI but this occurs neither through a direct binding of HDL to HCV particles nor through increase of HCV binding to SR-BI [25],[27],[29]. Since SR-BI locally increases cholesterol content of cell membranes by mediating lipid transfer from HDL, it has been proposed that HCV may exploit SR-BI physiological function to achieve its entry processes [25],[29]. However, direct evidence is missing that, by providing a docking port to HCV particle and/or by modulating post-binding events, SR-BI favors infection. Indeed, in contrast to CD81 and CLDN1 whose implications during HCV entry have been unambiguously demonstrated by mutational analysis in cells that were rendered susceptible to HCV entry upon their ectopic expression [9],[12],[13], the importance of SR-BI has only been addressed indirectly because of lack of cells in which similar complementation assays could be performed. Here we identified two cell types, of rat and human origins, that supported efficient HCV entry upon ectopic expression of SR-BI. Through the design of SR-BI mutants, i.e., in the extracellular and the cytoplasmic domains, we unravel important features of SR-BI functions regarding its involvement during HCV entry.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
###xml 67 70 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Susceptibility to HCVpp and HCVcc entry upon ectopic expression of HCV receptors
###end title 12
###begin p 13
###xml 175 178 175 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch1">[2]</xref>
###xml 179 182 179 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dubuisson1">[3]</xref>
###xml 183 186 183 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-vonHahn1">[4]</xref>
###xml 713 717 713 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Lavillette1">[14]</xref>
###xml 718 722 718 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 723 727 723 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset1">[29]</xref>
###xml 728 732 728 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Randall1">[31]</xref>
###xml 733 737 733 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Zeisel1">[32]</xref>
###xml 859 866 859 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000310-t001">Table 1</xref>
###xml 1320 1327 1320 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000310-t001">Table 1</xref>
###xml 1364 1374 1364 1374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s001">Figure S1C</xref>
###xml 1489 1497 1489 1497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g001">Figure 1</xref>
###xml 1502 1511 1502 1511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s001">Figure S1</xref>
###xml 1664 1667 1664 1667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Evans1">[9]</xref>
###xml 43 46 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 53 56 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 152 155 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 319 322 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 373 378 <span type="species:ncbi:9606">human</span>
###xml 417 420 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 794 799 <span type="species:ncbi:9606">human</span>
###xml 961 964 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1044 1049 <span type="species:ncbi:9606">human</span>
###xml 1135 1138 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1181 1186 <span type="species:ncbi:9606">human</span>
###xml 1233 1236 <span type="species:ncbi:10116">rat</span>
###xml 1550 1555 <span type="species:ncbi:9606">human</span>
###xml 1620 1623 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1703 1708 <span type="species:ncbi:9606">human</span>
###xml 1760 1763 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1794 1797 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Challenging the notion of liver tropism of HCV, most HCV receptors isolated so far are broadly expressed in different tissues, including those in which HCV does not replicate [2],[3],[4]. Particularly, the broadness of SR-BI expression makes difficult the investigation of the functional properties of this molecule in HCV infection, owing to the paucity of SR-BI-negative human cell lines in which susceptibility to HCV entry could be obtained upon ectopic expression. Furthermore, efficient SR-BI down-regulation in susceptible cell types, such as Huh-7 cells, is difficult to achieve without compromising cell viability (MD, DL, BB and FLC, data not published) and has raised different results between studies [14],[25],[29],[31],[32]. To overcome these difficulties, we screened a panel of human and rodent cell lines for absence or low SR-BI expression (Table 1). Aiming to design functional complementation assays, we ectopically expressed in these cells HCV receptors by transduction with a set of selectable retroviral vectors encoding human CD81, CLDN1 or SR-BI and, upon appropriate selection, we challenged these cells with HCV pseudo-particles (HCVpp). We detected one human liver endothelial cell line, SK-Hep1, and one rat hepatocarcinoma cell line, BRL3A, that became susceptible to entry with HCVpp-H77 (Table 1) and with HCVpp of other genotypes (Figure S1C) upon ectopic expression of SR-BI, provided hCD81 and hCLDN1 were also co-expressed, endogenously or ectopically (Figure 1 and Figure S1). While non hepato-carcinoma cells of human origin like e.g., 293T cells, have been rendered susceptible to HCV entry upon ectopic expression of hCLDN1 [9], this is the first report of a non human cell line that can be functionally complemented by HCV receptors, allowing efficient HCV entry.
###end p 13
###begin title 14
###xml 57 60 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
HCVpp entry upon ectopic hSR-BI co-expression with other HCV receptors.
###end title 14
###begin p 15
###xml 1607 1611 1599 1603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 589 592 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 670 673 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 720 725 <span type="species:ncbi:9606">human</span>
###xml 796 799 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1168 1171 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
(A) Endogenous and/or ectopic expression of hSR-BI and hCD81 in BRL3A, SK-Hep1, and Huh-7 cells was determined by flow cytometry. Parental cells were stained with hSR-BI (CLA-1 mAb, upper panel) or hCD81 (JS81 mAb, lower panel) antibodies (gray lines). The background of fluorescence was provided by staining the cells with the secondary antibodies only (dotted lines). Ectopic expression of hSR-BI in BRL3A and SK-Hep1 cells or of hCD81 in BRL3A cells was determined using the same antibodies (black lines). The results are representative of three independent experiments. (B) Results of HCV entry assays on BRL3A and SK-Hep1 cells ectopically expressing the indicated HCV receptors, and on PLC/PRF/5, Hep3B, and Huh-7 human hepatoma cells, endogenously expressing CD81, CLDN1, and SR-BI, using HCV pseudo-particles harboring H77-E1E2 glycoproteins (HCVpp), control viral particles harboring the VSV-G glycoprotein (VSV-Gpp; diluted 1/100), or no glycoprotein (noENVpp). The viral particles were produced in cell culture media devoid of serum lipoproteins. Results display average infectious titers, expressed as GFP IU/ml (mean+/-SD; n = 3). ND, not determined. (C) HCV entry assays using HCVpp produced in serum-free medium in the presence of 6 microg/ml cholesterol-HDL. The results show the fold increases of infection (mean+/-SD; n = 3) determined by calculating the ratios between average infectious titers determined in the presence or absence of HDL. No changes of infectivity with VSV-Gpp control particles were detected under these experimental conditions (data no shown), as reported previously [25].
###end p 15
###begin title 16
HCVpp entry in receptor-complemented target cells.
###end title 16
###begin p 17
###xml 92 93 92 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 123 124 123 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 131 132 131 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 164 165 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 172 173 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 206 207 204 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
HCVpp entry of genotype 1a (H77) harbouring the GFP marker gene. (++), titres higher than 105 IU/ml; (+), titres between 103 and 105 IU/ml; (+/-), titres between 102 and 103 IU/ml; (-), titres lower than 102 IU/ml, which corresponds to the threshold of detection of infected cells by FACS analysis.
###end p 17
###begin p 18
###xml 13 18 <span type="species:ncbi:9606">human</span>
Detection of human CD81 using JS-81 antibody on the surface of the indicated cells by flow cytometry. (-), MFI (mean fluorescent intensity) shift of 1; (+), MFI shift between 1 and 50; (++), MFI shift over 50.
###end p 18
###begin p 19
###xml 13 18 <span type="species:ncbi:9606">human</span>
###xml 95 100 <span type="species:ncbi:10090">mouse</span>
Detection of human Claudin-1 (CLDN1) in lysates of the indicated cells by immuno-blotting with mouse anti-Claudin-1 antibodies (Interchim). (-), signal intensity 5-fold lower than that detected in Huh-7 cells; (+), signal intensity between 5-fold lower and 5-fold higher than that detected in Huh-7 cells; (++), signal intensity 5-fold higher than that detected in Huh-7 cells.
###end p 19
###begin p 20
###xml 13 18 <span type="species:ncbi:9606">human</span>
Detection of human SR-B1 using the CLA-1 antibody on the surface of the indicated cells by flow cytometry. (-), MFI shift of less than 2; (+/-), MFI shift between 2 and 6; (+), MFI shift between 6 and 20; (++), MFI shift over 20.
###end p 20
###begin p 21
###xml 96 105 96 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g001">Figure 1A</xref>
###xml 110 120 110 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s001">Figure S1A</xref>
###xml 247 256 247 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g001">Figure 1B</xref>
###xml 261 271 261 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s001">Figure S1D</xref>
###xml 408 426 408 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s001">Figure S1A and S1B</xref>
###xml 428 439 428 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s005">Protocol S1</xref>
###xml 715 724 715 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g001">Figure 1B</xref>
###xml 729 739 729 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s001">Figure S1D</xref>
###xml 898 907 898 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g001">Figure 1B</xref>
###xml 935 939 935 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch2">[12]</xref>
###xml 940 944 940 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Hsu1">[13]</xref>
###xml 945 949 945 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch4">[33]</xref>
###xml 950 954 950 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-vonHahn2">[34]</xref>
###xml 1015 1024 1015 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g001">Figure 1B</xref>
###xml 1071 1075 1071 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch2">[12]</xref>
###xml 1076 1080 1076 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Hsu1">[13]</xref>
###xml 1081 1085 1081 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Lavillette1">[14]</xref>
###xml 1086 1090 1086 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch4">[33]</xref>
###xml 1168 1178 1168 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s001">Figure S1A</xref>
###xml 1197 1206 1197 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s002">Figure S2</xref>
###xml 331 334 <span type="species:ncbi:10116">rat</span>
###xml 479 482 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 868 873 <span type="species:ncbi:9606">human</span>
###xml 1061 1064 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1410 1413 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1487 1490 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Over-expression of hSR-BI in SK-Hep1-CLDN1 cells that express very low endogenous SR-BI levels (Figure 1A and Figure S1A) resulted in ca. 10-fold increased HCVpp titers, i.e., titers that were only 2-fold lower than those obtained in Huh-7 cells (Figure 1B and Figure S1D). In contrast, no or undetectable expression of endogenous rat SR-BI could be detected by immunoblotting and by RT-qPCR in BRL3A cells (Figure S1A and S1B, Protocol S1). Furthermore, no or hardly detectable HCV entry could be found in BRL3A cells ectopically expressing hSR-BI only or expressing both hCD81 and hCLDN1 (BRL3A-CD81-CLDN1 cells), despite full entry susceptibility of control pseudo-particles pseudotyped with VSV-G glycoprotein (Figure 1B and Figure S1D). Expression of hSR-BI in BRL3A-CD81-CLDN1 cells allowed HCVpp entry at titers similar to those detected in PLC/PRF/5 and Hep3B human hepato-carcinoma cells (Figure 1B), used in previous reports [12],[13],[33],[34], and ca. 8-fold lower than those obtained with Huh-7 cells (Figure 1B), which are the most susceptible to HCV entry [12],[13],[14],[33]. Of note, co-expression of hCD81, hCLDN1 and/or hSR-BI did not modify total (Figure S1A) or cell surface (Figure S2) expression levels of either of these entry factors. Hence, our results unambiguously demonstrated for the first time that expression of SR-BI - in combination with CD81 and CLDN1 - is required to allow HCV entry and support the notion that hSR-BI is an essential entry factor of HCV.
###end p 21
###begin p 22
###xml 151 155 151 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Meunier1">[28]</xref>
###xml 161 165 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset1">[29]</xref>
###xml 176 180 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Catanese1">[26]</xref>
###xml 181 185 181 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux1">[27]</xref>
###xml 186 190 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset2">[30]</xref>
###xml 493 502 493 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g001">Figure 1C</xref>
###xml 629 638 629 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s002">Figure S2</xref>
###xml 81 84 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 209 214 <span type="species:ncbi:9606">human</span>
###xml 245 248 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 471 476 <span type="species:ncbi:9606">human</span>
We used these complementation assays to characterize the properties of hSR-BI in HCV entry. HDL, the main ligand of SR-BI, enhances infection of HCVpp [25],[28],[29] and HCVcc [26],[27],[30] in SR-BI-positive human cells that are susceptible to HCV entry like, e.g., Huh-7, HepG2-CD81, PLC/PRF/5, SW13 or Hep3B cells. We found that HCVpp entry into both BRL3A-CD81-CLDN1-SR-BI and SK-Hep1-CLDN1-SR-BI cells was stimulated by HDL to levels comparable to those detected in human hepatoma cells (Figure 1C). No change of cell surface (co)-expression of hSR-BI and/or hCD81 could be detected upon incubation of these cells with HDL (Figure S2 and data not shown).
###end p 22
###begin p 23
###xml 174 175 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 767 770 767 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Evans1">[9]</xref>
###xml 831 840 831 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g002">Figure 2A</xref>
###xml 1233 1242 1233 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g002">Figure 2A</xref>
###xml 1672 1681 1672 1681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g002">Figure 2B</xref>
###xml 1729 1738 1729 1738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g001">Figure 1B</xref>
###xml 1743 1753 1743 1753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s001">Figure S1D</xref>
###xml 1907 1916 1907 1916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g002">Figure 2B</xref>
###xml 65 68 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 531 534 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 854 857 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 943 946 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1111 1114 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1303 1306 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1545 1548 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1818 1821 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Next, we confirmed the above findings using cell culture-derived HCV (HCVcc). In comparison to HCVcc infection of Huh-7.5 cells, for which viral infectious titers (above 1x106 i.u./ml) could be assessed by immunostaining for Core protein, the same viral stocks resulted in lower infectivity levels in SK-Hep1-CLDN1-SR-BI target cells (data not shown), precluding accurate determination of infectious titers by immuno-detection. Therefore, we used a sensitive and quantitative real-time RT-PCR (RT-qPCR) assay to measure changes in HCV RNA at 4 hr, 12 hr and 72 hr post-infection with HCVcc. Inoculation of HCVcc on SK-Hep1-CLDN1 and SK-Hep1-CLDN1-SR-BI cells yielded strong RT-qPCR signals at 4 hr post-infection, indicating binding and/or capture of viral particles [9], that progressively declined with 10-30 fold loss at 12 hr (Figure 2A). Yet, while HCV RNA decreased again by ca. 15-fold in the parental SK-Hep1-CLDN1 cells at 72 hr, the HCV RNA levels increased in SK-Hep1-CLDN1-SR-BI cells at 72 hr vs. 12 hr post-infection but were strongly reduced when such target cells were treated during 72 hr with HCV replication inhibitors (BILN2061, an NS3 protease inhibitor, or 2'-C-methyl-adenosine, an NS5B polymerase inhibitor) (Figure 2A). Altogether, these results indicated that the detection of HCV RNAs revealed true HCVcc entry of these cells, leading to viral replication, rather than just residual cell attachment of viral particles. Overall, the co-expression of SR-BI and CLDN1 in SK-Hep1 cells allowed ca. 10 to 20 fold increased HCV RNA detection at this 72 hr time point as compared to SK-Hep1 cells expressing CLDN1 alone or none of these entry factors (Figure 2B), consistent with results obtained with HCVpp (Figure 1B and Figure S1D). Importantly, addition of HDL during infection could stimulate HCV RNA detection in SR-BI-expressing SK-Hep1-CLDN1 cells but not in the parental cells (Figure 2B).
###end p 23
###begin title 24
###xml 57 60 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
HCVcc entry upon ectopic hSR-BI co-expression with other HCV receptors.
###end title 24
###begin p 25
###xml 679 680 677 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 689 690 685 686 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1909 1910 1895 1896 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 71 74 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 453 456 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 560 563 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 633 636 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 889 892 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1070 1073 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1251 1254 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1371 1374 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1554 1557 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1830 1833 <span type="species:ncbi:10116">rat</span>
(A) Results of HCVcc entry assays, assessed by measuring intracellular HCV RNA level at 4, 12, and 72 hr post-infection, in SK-Hep1 cells ectopically expressing CLDN1 vs. CLDN1 and SR-BI, using cell culture-produced HCVcc in the absence or in the presence of NS3 protease inhibitor and NS5B-dependent RNA synthesis inhibitor (BILN2051 and 2'-C-methyl-adenosine, respectively, kindly provided by FV Chisari). Results are standardized with respect to the HCV RNA level obtained at 72 hr on non-treated SK-Hep1-CLDN1-SR-BI cells (mean+/-SD; n = 3). Intracellular HCV RNA levels of SK-Hep1-CLDN1-SR-BI was on average 440-fold lower than HCV RNA levels measured in Huh7.5 cell (4.7x103+/-2.4x102 genome copies per microg cellular mRNA) using the same HCVcc supernatants. (B) Results of HCVcc entry assays, assessed at 72 hr post-infection, in SK-Hep1 cells ectopically expressing the indicated HCV entry factors, using cell culture-produced HCVcc in the absence (white bars) or presence (black bars) of 0.6 microg/ml cholesterol-HDL. Results are standardized with respect to HCV RNA level obtained in the absence of HDL on wt SR-BI-expressing SK-Hep1-CLDN1 cells (mean+/-SD; n = 5). Similar experiments in BRL3A-CD81-CLDN1-SR-BI cells allowed detection of HCV RNA at 72 hr, which was specifically increased upon treatment with HDL, and revealed differences upon expression of HCV entry factors (data not shown) consistent with the results obtained with HCVpp. However, kinetic experiments and use of replication inhibitors did not allow firm demonstration of HCV replication in these cells. (C) Dose-response curves for the SR-BI-dependent free cholesterol efflux and for HDL-CE uptake determined in BRL3A-CD81-CLDN1 and SKHep1-CLDN1 cells ectopically expressing, or not, hSR-BI, or in Fu5AH cells expressing high endogenous levels of rat SR-BI. Cholesterol efflux is expressed as the percentage of total labelled 3H-cholesterol released to the medium. Selective HDL-CE uptake is expressed as the percentage of labelled HDL-CE delivered to cells per microg of cell protein. The values represent the means +/-SD of three experiments.
###end p 25
###begin p 26
###xml 20 24 20 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 25 29 25 29 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset1">[29]</xref>
###xml 30 34 30 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux2">[35]</xref>
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 379 383 379 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-LeGoff1">[36]</xref>
###xml 398 399 398 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 451 455 451 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-delaLleraMoya1">[37]</xref>
###xml 469 478 469 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g002">Figure 2C</xref>
###xml 600 618 600 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s001">Figure S1A and S1B</xref>
###xml 774 792 774 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s001">Figure S1A and S1B</xref>
###xml 952 961 952 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g002">Figure 2C</xref>
###xml 1103 1112 1103 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g001">Figure 1C</xref>
###xml 1117 1126 1117 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g002">Figure 2B</xref>
###xml 727 730 <span type="species:ncbi:10116">rat</span>
###xml 763 766 <span type="species:ncbi:10116">rat</span>
###xml 1059 1062 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
In previous studies [25],[29],[35], it was proposed that one of the mechanisms by which HDL enhances infection could involve SR-BI physiological activity. To address this possibility, we first sought to demonstrate whether SR-BI expressed in the BRL3A and SK-Hep1 cellular backgrounds was functional and could mediate lipid transfer, i.e., selective uptake of 3H-CE-labelled HDL [36] and efflux of 3H-cholesterol to phospholipid cholesterol acceptors [37]. As shown in Figure 2C, while BRL3A-CD81-CLDN1 cells could not or hardly mediate lipid transfer most likely owing to undetectable SR-BI levels (Figure S1A and S1B), ectopic expression of hSR-BI in these cells resulted in efficient lipid uptake and efflux, as compared to rat hepatoma Fu5AH cells expressing rat SR-BI (Figure S1A and S1B) used as positive controls. Likewise, over-expression of hSR-BI in SK-Hep1-CLDN1 cells resulted in efficient cholesterol efflux as compared to parental cells (Figure 2C). Importantly, these results were consistent with the restoration of HDL-mediated enhancement of HCV entry upon ectopic expression of SR-BI (Figure 1C and Figure 2B).
###end p 26
###begin p 27
###xml 244 247 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Altogether, these results established that BRL3A-CD81-CLDN1 and SK-Hep1-CLDN1 cells provide original and useful tools for SR-BI complementation assays and render for the first time mutagenetic approaches possible to study the roles of SR-BI in HCV entry.
###end p 27
###begin title 28
Function of SR-BI intracellular domain
###end title 28
###begin p 29
###xml 962 971 962 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3A</xref>
###xml 1085 1094 1085 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3A</xref>
###xml 1208 1212 1208 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Flint1">[38]</xref>
###xml 1213 1217 1213 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Owsianka1">[39]</xref>
###xml 1231 1234 1231 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Scarselli1">[7]</xref>
###xml 1346 1349 1346 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Evans1">[9]</xref>
###xml 1350 1354 1350 1354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Owsianka2">[40]</xref>
###xml 1355 1359 1355 1359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Zhang1">[41]</xref>
###xml 1360 1364 1360 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bertaux1">[42]</xref>
###xml 1426 1430 1426 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux1">[27]</xref>
###xml 1431 1435 1431 1435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux2">[35]</xref>
###xml 1436 1440 1436 1440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Lavillette3">[43]</xref>
###xml 1818 1827 1818 1827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3B</xref>
###xml 1849 1858 1849 1858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3B</xref>
###xml 292 295 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 308 311 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 396 401 <span type="species:ncbi:9606">human</span>
###xml 445 451 <span type="species:ncbi:10090">murine</span>
###xml 493 498 <span type="species:ncbi:9606">human</span>
###xml 587 592 <span type="species:ncbi:9606">human</span>
###xml 1058 1061 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1135 1138 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1324 1327 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
We tested a panel of well-characterized SR-BI mutants in receptor complementation assays in order to address the properties of its intracellular and extracellular domains. Upon introduction in BRL3A-CD81-CLDN1 or SK-Hep1-CLDN1 cells, each SR-BI mutant was studied for its capacity to mediate HCV-E2 binding, HCV entry and HDL-induced infection-enhancement. Because some mutations introduced into human SR-BI were originally characterized in the murine ortholog, which shares 79% identity with human SR-BI (data not shown), we also characterized lipid uptake and efflux mediated by these human SR-BI mutants. To address the functions of the SR-BI intracellular domain, we expressed several SR-BI mutants or isoforms in BRL3A-CD81-CLDN1 and SK-Hep1-CLDN1 cells. By adjusting the input of vectors used to transduce the mutant/chimeric receptors in these cells, we obtained cell surface expression levels comparable to that of wt SR-BI as detected by FACS analysis (Figure 3A). To investigate the capacity of these modified SR-BI receptors to mediate binding of HCV surface glycoproteins (Figure 3A), we used a soluble recombinant form of HCV E2 glycoprotein (sE2), which harbors determinants of binding to CD81 [38],[39] and to SR-BI [7]. Of note, sE2-based binding assays may not fully represent all the binding parameters of HCV particles to CD81 [9],[40],[41],[42]. Yet, we decided to use this assay since in previous studies [27],[35],[43], we found that SR-BI-binding of HCVpp parallels that of sE2 although the latter is more sensitive than binding of HCVpp. Importantly, all these different target cells induced comparable entry levels of control viral particles harboring the VSV-G glycoprotein (VSV-Gpp), with less than 30% variation of VSV-Gpp titers as compared to those detected on wt SR-BI-expressing cells (Figure 3B). Note that although Figure 3B provides the raw data, the small differences of VSV-Gpp titers between the different SR-BI mutant-expressing cell lines could be used to normalize HCVpp infectivity.
###end p 29
###begin title 30
HCVpp entry in BRL3A-CD81-CLDN1 cells expressing SR-BI intracellular domain mutants.
###end title 30
###begin p 31
###xml 621 630 619 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g001">Figure 1A</xref>
###xml 1006 1014 1002 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g006">Figure 6</xref>
###xml 1579 1580 1573 1574 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1955 1959 1943 1947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
(A) Cell surface expression (white bars) and sE2 binding (black bars) of SR-BI mutants/isoforms was determined using anti-SR-BI antibody (CLA-1 mAb) and soluble E2 protein (sE2), respectively. The results of cell surface expression, analyzed by flow cytometry of BRL3A-CD81-CLDN1 cells transduced with retroviral vectors carrying the indicated SR-BI mutants, are expressed as the average percentages of GEOmean (geometric mean) fluorescence shifts (mean+/-SD; n = 3) detected between mutant receptor-expressing cells and parental (-) cells, relative to cells expressing wild-type SR-BI (ca. 20-fold of GEOmean shift, see Figure 1A) set to 100. The results of sE2 binding are expressed as the average percentages of GEOmean fluorescence shifts (mean+/-SD; n = 3) detected in parental BRL3A cells (-) or in BRL3A cells only expressing the indicated SR-BI mutants that were incubated with sE2-containing medium vs. sE2-free medium, relative to cells expressing wild-type SR-BI (ca. 10-fold GEOmean shift, see Figure 6) set to 100. Cell surface expression of SR-BI mutants in these latter cells was similar to that detected in the SR-BI-expressing BRL3A-CD81-CLDN1 cells (data not shown). Cell surface expression of CD36 (*, data not shown) was verified using a CD36 antibody (FA6-152, abcam). (B) Effect of SR-BI mutations on infectivity of HCVpp produced in serum-free media. The results of infectivity (mean+/-SD; n = 5) are expressed relative to the infectious titers of HCVpp or of control VSV-Gpp particles determined on wt SR-BI-expressing BRL3A-CD81-CLDN1 cells (input ca. 104 GFP IU) set to 100. (C) Results of HCVpp infection-enhancement induced by HDL (6 microg/ml cholesterol-HDL), expressed as ratios between average infectious titers determined in the presence or absence of HDL (mean+/-SD; n = 5). No changes of infectivity of VSV-Gpp control particles were detected under these experimental conditions (data not shown), as reported previously [25]. (D) Relative capacities of SR-BI mutants to mediate HDL-CE uptake (black bars) and free cholesterol efflux (white bars) relative to wt SR-BI set to 100 (mean+/-SD; n = 3). ND, not determined.
###end p 31
###begin p 32
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Connelly1">[44]</xref>
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Connelly2">[45]</xref>
###xml 92 96 92 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Gu1">[46]</xref>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Gu1">[46]</xref>
###xml 357 366 357 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3A</xref>
###xml 392 395 392 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Scarselli1">[7]</xref>
###xml 429 438 429 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3B</xref>
###xml 782 791 782 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3C</xref>
###xml 27 30 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 656 659 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
First, we investigated the HCV entry properties of a chimeric SR-BI/CD36 receptor [44],[45],[46], in which the two transmembrane domains and cytoplasmic tails of SR-BI were replaced by those of CD36, a close homolog of SR-BI that mediates high-affinity HDL binding but not efficient lipid transfer [46]. Cells expressing wt CD36 did not induce sE2 binding (Figure 3A), as reported previously [7], nor did they allow HCVpp entry (Figure 3B). In contrast, as compared to wt SR-BI, the SR-BI/CD36 chimera mediated about 3-fold reduced sE2 binding, in agreement with the 3-fold reduction of HCVpp entry, after VSV-Gpp normalization. Despite this reduced basal HCV entry, this mutant receptor allowed HDL-mediated infection-enhancement at levels similar to those obtained with wt SR-BI (Figure 3C).
###end p 32
###begin p 33
###xml 334 338 330 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Connelly2">[45]</xref>
###xml 548 552 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Eckhardt1">[47]</xref>
###xml 553 557 549 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Mulcahy1">[48]</xref>
###xml 637 641 633 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Connelly2">[45]</xref>
###xml 642 646 638 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Eckhardt1">[47]</xref>
###xml 677 686 673 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3D</xref>
###xml 870 879 862 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3A</xref>
###xml 1097 1109 1089 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3A&#8211;3C</xref>
###xml 62 65 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1336 1339 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
To examine further the involvement of the SR-BI endodomain in HCV entry, we expressed in BRL3A-CD81-CLDN1 cells SR-BI forms harboring alterations of its C-terminal cytoplasmic tail, which contains signals associated to SR-BI expression, localization and/or function: DeltaCterm, a SR-BI mutant lacking the C-terminal cytoplasmic tail [45], and SR-BII, an alternative mRNA splice variant of SR-BI with an entirely different cytoplasmic C terminus that promotes more rapid HDL/SR-BII endocytosis as compared to SR-BI and alternative signaling events [47],[48]. Both forms of SR-BI were previously shown to mediate efficient binding of HDL [45],[47] and to induce lipid transfer (Figure 3D). We adjusted SR-BII cell surface expression to levels similar to those of SR-BI, but albeit all our efforts the expression levels of the DeltaCterm mutant remained two-fold reduced (Figure 3A). Similar to results obtained with the SR-BI/CD36 chimera, these altered SR-BI receptors induced reduced sE2 binding (by 2-3 fold) and HCVpp entry (by 2-fold) but wild type level of HDL-induced infection-enhancement (Figure 3A-3C). Altogether, the results obtained with SR-BII, SR-BI/CD36 or DeltaCterm mutants indicated that while the cytoplasmic tail of SR-BI does not seem to be involved in stimulation of infection by HDL, it could influence the basal HCV entry efficiency. Furthermore, the results on sE2 binding suggested that the level of cell attachment of viral particles was altered for these mutants, which could reflect alterations of receptor affinity, density, localization and/or turnover at the plasma membrane.
###end p 33
###begin p 34
###xml 268 272 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Ikemoto1">[49]</xref>
###xml 510 514 506 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Ikemoto1">[49]</xref>
###xml 515 519 511 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Komori1">[50]</xref>
###xml 760 768 756 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3</xref>
###xml 995 1004 991 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s003">Figure S3</xref>
###xml 1254 1258 1250 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Eckhardt2">[51]</xref>
###xml 1362 1366 1358 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Gu1">[46]</xref>
###xml 1448 1452 1440 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Gu1">[46]</xref>
###xml 1453 1457 1445 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Eckhardt2">[51]</xref>
###xml 1541 1550 1533 1542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3A</xref>
###xml 1617 1626 1609 1618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3B</xref>
###xml 103 106 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 710 713 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 894 897 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1059 1062 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1606 1609 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1723 1726 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
We therefore sought to investigate specific determinants of SR-BI cytoplasmic tail that could modulate HCV entry. We first generated a mutant SR-BI receptor, DeltaAKL, in which we removed a carboxy-terminal motif of SR-BI that mediates interaction with PDZKI or CLAMP [49]. PDZKI is a four-PDZ-domain-containing protein that is associated with SR-BI in hepatocytes and that may stabilize SR-BI in the sinusoidal plasma membrane by modulating its intracellular transport, localization, assembly and scaffolding [49],[50]. Compared to wt SR-BI, we found that the deletion of PDZKI-associating motif slightly reduced mutant receptor expression and sE2 binding by less than 2-fold but had no or minor influence on HCV entry and HDL-mediated infection enhancement (Figure 3). Furthermore, when PDZK1 was knocked-down in Huh-7 cells using siRNAs, we found that the PDZK1 down-regulated cells induced HCV entry and infection-enhancement at levels identical to those detected in unmodified Huh-7 cells (Figure S3). Thus, PDZK1 down-regulation had almost no effect on HCV entry, in agreement with the results of AKL motif deletion. Next, we generated alternative cytoplasmic-tail mutants: SES, in which the endocytosis motif of SR-BII was functionally introduced [51], and 2CS, in which the two acylation sites of the SR-BI carboxy-terminal cytoplasmic tail were mutated [46]. Like the DeltaAKL mutant, these alternative mutants allow efficient HDL binding [46],[51]. Despite similar cell surface expression and sE2 binding, as compared to wt SR-BI (Figure 3A), the SES and 2CS mutants induced about 2-fold reduced HCV entry (Figure 3B), hence suggesting a role of the endocytic trafficking and/or membrane localization of SR-BI in HCV entry.
###end p 34
###begin p 35
###xml 187 196 187 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s004">Figure S4</xref>
###xml 490 498 490 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g004">Figure 4</xref>
###xml 611 619 611 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3</xref>
###xml 624 633 624 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s004">Figure S4</xref>
###xml 646 654 646 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g004">Figure 4</xref>
###xml 1039 1048 1039 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g003">Figure 3D</xref>
###xml 39 42 <span type="species:ncbi:10116">rat</span>
###xml 107 112 <span type="species:ncbi:9606">human</span>
###xml 836 839 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
While these results were obtained in a rat hepato-carcinoma background, they were largely confirmed in the human background of SK-Hep1-CLDN1 cells expressing the different SR-BI mutants (Figure S4). Furthermore, we tested a subset of these SR-BI mutants in HCVcc infection assays. While CD36 expression in SK-Hep1-CLDN1 cells did not induce infection of HCVcc, the SR-BI/CD36 chimera and the SES mutant were functional, but, for the latter, infection was reduced in comparison to wt SR-BI (Figure 4), in line with results obtained with HCVpp infection assays. Finally, we found that HDL stimulated HCVpp entry (Figure 3 and Figure S4) and HCVcc (Figure 4) at similar levels for SR-BI cytoplasmic tail mutants as compared to wt SR-BI. Altogether, these results indicated that the C-terminal cytoplasmic tail of SR-BI modulates the basal HCV entry process, but seems not to influence HDL-mediated infection-enhancement. This latter observation is consistent with the fact that the SR-BI C-terminal mutants mediated efficient lipid transfer (Figure 3D).
###end p 35
###begin title 36
HCVcc entry in SK-Hep1-CLDN1 cells expressing SR-BI mutants.
###end title 36
###begin p 37
###xml 359 368 359 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g002">Figure 2A</xref>
###xml 316 319 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The SR-BI mutants tested were the SR-BI/CD36 chimera and the SES mutants, altering SR-BI intracellular domain, the Q402R/E418R, N173Q, and G420H-G424H mutants, altering SR-BI ectodomain. (A) Effect of SR-BI mutations on infectivity of HCVcc produced under standard conditions and assessed by measuring intracellular HCV RNA level at 72 hr post-infection (see Figure 2A). The results of infectivity (mean+/-SD; n = 3) are expressed relative to HCVcc infection of wt SR-BI-expressing SK-Hep1-CLDN1 cells, which was set to 100. (B) Results of HCVcc infection-enhancement induced by HDL (0.6 microg/ml cholesterol-HDL) on wt SR-BI-expressing SK-Hep1-CLDN1 cells, expressed as ratios relative to infection in the absence of HDL of the same cells set to 100 (mean+/-SD; n = 3). Similar experiments in BRL3A-CD81-CLDN1 cells expressing these SR-BI mutants were performed (data not shown) and were consistent with the results obtained in SK-Hep1-CLDN1 cells.
###end p 37
###begin title 38
Functions of the extracellular domain
###end title 38
###begin p 39
###xml 354 363 354 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5D</xref>
###xml 522 526 522 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Calvo1">[18]</xref>
###xml 675 679 675 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Gu2">[52]</xref>
###xml 760 769 760 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5D</xref>
###xml 914 923 914 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5A</xref>
###xml 993 1002 993 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5B</xref>
###xml 1234 1243 1234 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5C</xref>
###xml 200 203 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 592 597 <span type="species:ncbi:10090">mouse</span>
###xml 602 607 <span type="species:ncbi:9606">human</span>
###xml 1104 1107 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1295 1298 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
To address the functions of the SR-BI ectodomain, we expressed SR-BI mutants that exhibited reduced HDL binding and/or lipid transfer properties. The capacity of either mutant to mediate sE2 binding, HCV entry and HDL-mediated infection-enhancement was compared with wt SR-BI or with the E210G ectodomain mutant, exhibiting wt lipid transfer properties (Figure 5D). First, we expressed a shorter isoform of SR-BI (SR-BI-Short), produced by alternative splicing of SR-BI mRNA that removes 100-amino-acids of the ectodomain [18], and the M159R point mutant, targeting a motif conserved between mouse and human SR-BI that has been shown to reduce HDL binding and lipid transfer [52]. The decreased levels of lipid uptake and efflux were verified for each mutant (Figure 5D). Upon expression in BRL3A-CD81-CLDN1 cells, these modified SR-BI receptors mediated no (SR-BI-Short) or hardly detectable (M159R) sE2 binding (Figure 5A) and reduced HCVpp entry by over 10-fold, in comparison to wt SR-BI (Figure 5B). These results therefore highlighted the importance of E2 attachment to the SR-BI ectodomain in the HCV entry process. Moreover, these mutants were unable to induce infection-enhancement when HDL was added during HCVpp infection (Figure 5C), which could be due to their inability to mediate HCV binding or, alternatively, from their inability to bind HDL and/or to mediate lipid transfer.
###end p 39
###begin title 40
HCVpp entry in BRL3A-CD81-CLDN1 cells expressing SR-BI ectodomain mutants.
###end title 40
###begin p 41
###xml 627 636 625 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g001">Figure 1A</xref>
###xml 1015 1023 1011 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g006">Figure 6</xref>
###xml 1718 1719 1712 1713 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 2097 2101 2085 2089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
(A) Cell surface expression (white bars) and sE2 binding (black bars) of SR-BI mutants/isoforms as determined using anti-SR-BI antibody (CLA-1 mAb) and soluble E2 protein (sE2), respectively. The results of cell surface expression, analyzed by flow cytometry of BRL3A-CD81-CLDN1 living cells transduced with retroviral vectors carrying the indicated SR-BI mutants, are expressed as the average percentages of GEOmean (geometric mean) fluorescence shifts (mean+/-SD; n = 3) detected between mutant receptor-expressing cells and parental (-) cells, relative to cells expressing wild-type SR-BI (ca. 20-fold of GEOmean shift, see Figure 1A) set to 100. The results of sE2 binding are expressed as the average percentages of GEOmean fluorescence shifts (mean+/-SD; n = 3) detected in parental BRL3A cells (-) or in BRL3A cells only expressing the indicated SR-BI mutants that were incubated with sE2-containing medium vs. sE2-free medium, relative to cells expressing wild-type SR-BI (ca. 10-fold of GEOmean shift, see Figure 6) set to 100. Cell surface expression of SR-BI mutants in these latter cells was similar to that detected in the SR-BI-expressing BRL3A-CD81-CLDN1 cells (data not shown). Cell surface expression of SR-BI-Short (*, data not shown) was verified by immuno-blotting using an antibody against SR-BI C-terminus (400-104, Novus) on surface-biotinylated proteins that were purified with streptavidin-coated beads. (B) Effect of SR-BI mutations on infectivity of HCVpp produced in serum-free media. The results of infectivity (mean+/-SD; n = 5) are expressed relative to the infectious titers of HCVpp or of control VSV-Gpp particles determined on wt SR-BI-expressing BRL3A-CD81-CLDN1 cells (input ca. 104 GFP i.u.), set to 100. (C) Results of HCVpp infection-enhancement induced by HDL (6 microg/ml cholesterol-HDL), expressed as ratios between average infectious titers determined in the presence or absence of HDL (mean+/-SD; n = 5). No changes of infectivity of VSV-Gpp control particles were detected under these experimental conditions (data not shown), as reported previously [25]. (D) Relative capacities of SR-BI mutants to mediate HDL-CE uptake (black bars) and free cholesterol efflux (white bars) relative to wt SR-BI set to 100 (mean+/-SD; n = 3). ND, not determined.
###end p 41
###begin p 42
###xml 174 178 174 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Nieland1">[53]</xref>
###xml 585 589 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 590 594 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset1">[29]</xref>
###xml 678 682 678 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 683 687 683 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset1">[29]</xref>
###xml 738 746 738 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g006">Figure 6</xref>
###xml 889 893 885 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 894 898 890 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux1">[27]</xref>
###xml 899 903 895 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset1">[29]</xref>
###xml 1125 1133 1121 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g006">Figure 6</xref>
###xml 1382 1390 1378 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g006">Figure 6</xref>
###xml 1603 1611 1599 1607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g006">Figure 6</xref>
###xml 2038 2042 2034 2038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Gu2">[52]</xref>
###xml 2043 2047 2039 2043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Gu3">[54]</xref>
###xml 2061 2070 2057 2066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5D</xref>
###xml 2193 2202 2189 2198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5A</xref>
###xml 2266 2275 2262 2271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5A</xref>
###xml 2334 2343 2330 2339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5B</xref>
###xml 2519 2528 2515 2524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5C</xref>
###xml 2609 2618 2605 2614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5D</xref>
###xml 2862 2878 2858 2874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5C and 5D</xref>
###xml 366 369 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 575 578 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 848 851 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1740 1743 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 2451 2454 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 2947 2950 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
BLTs (block lipid transfer; BLT-1 to BLT-4) are small lipid transport inhibitors originally identified in a high-throughput chemical screen of intact mSR-BI-expressing cells [53]. They inhibit SR-BI-dependent selective cholesterol uptake and efflux from and to HDL, but do not block HDL binding. We, and others, previously showed that BLTs also inhibit HDL-mediated HCV infection-enhancement, which, together with alternative results using SR-BI blocking antibodies or SR-BI down-regulation, suggested the possibility that the SR-BI physiological activity is involved during HCV entry [25],[29]. Surprisingly, here we found that BLT-4, characterized in several previous studies [25],[29], inhibited sE2 binding to SR-BI-expressing BRL3A (Figure 6) and CHO (data not shown) cells, at the same concentrations as those that proved to be effective for HCV entry inhibition, i.e., 15-50 microM [25],[27],[29]. Similar inhibition of HCVpp infectivity and sE2 binding was detected with other BLTs (data not shown). While sE2 readily bound BRL-CD81-CLDN1 cells, no inhibition of sE2 binding by BLTs could be detected on those cells (Figure 6 and data not shown). Moreover, while co-expression of CD81 and SR-BI increased sE2 binding as compared to BRL3A cells expressing either entry factor, BLT-4 reduced sE2 binding to BRL-CD81-CLDN1-SR-BI at the levels detected on BRL-CD81-CLDN1 cells (Figure 6). These results indicated that BLTs specifically inhibited sE2 binding to SR-BI. Moreover, HDL did not increase sE2 binding to either SR-BI or CD81 and did not modify inhibition of sE2 binding to SR-BI by BLT-4 (Figure 6). The unexpected finding that BLTs inhibit sE2/SR-BI binding further lent support for a requirement of sE2 binding to SR-BI for HCV entry. However, since the use of BLTs could not unambiguously demonstrate that HDL-mediated infection-enhancement requires SR-BI-dependent lipid transfer, next, we expressed and analyzed effects of SR-BI ectodomain mutants E418R, Q402R and Q402R/E418R that have reduced lipid uptake properties [52],[54], as shown in Figure 5D. Similar levels of cell surface expression for either mutant could be detected by FACS analysis, as compared to wt SR-BI (Figure 5A). These SR-BI mutants exhibited 5-15 fold reduced sE2 binding (Figure 5A), which was correlated with a lower infectivity of HCVpp (Figure 5B), in agreement with results obtained with the M159R and SR-BI-Short mutants. When HDL was added during the HCV entry assay, we found that the extent of infection-enhancement (Figure 5C) was correlated to the capacity of these SR-BI mutants to mediate lipid uptake (Figure 5D). For example, while E418R that shows 60% reduced lipid uptake capacity induced wild-type HDL-mediated infection-enhancement, the most disabled lipid transfer mutants, Q402R and Q402R-E418R, had lost almost all infection-enhancement capacity (Figure 5C and 5D). Collectively, the results demonstrated that SR-BI functions as an HCV entry factor by providing both cell surface binding sites and lipid uptake activity.
###end p 42
###begin title 43
Inhibition of sE2 binding to SR-BI by BLT-4 compound.
###end title 43
###begin p 44
###xml 330 334 314 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Nieland1">[53]</xref>
BRL3A cells expressing the indicated entry factors were incubated for 1 hr at 37degreesC with soluble E2 protein (sE2) (plain lines) or without sE2 (dotted lines) at saturating concentrations, after pre-incubation for 45 min at 37degreesC with (gray lines) or without (black lines) 50 microM BLT-4 (Chembridge), a SR-BI inhibitor [53], and with (left panels) or without (right panels) HDL (6 microg/ml cholesterol-HDL). SR-BI expression was not modified by the incubation with BLT-4 (data not shown). The data are representative of three independent experiments.
###end p 44
###begin p 45
###xml 68 72 68 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Gu2">[52]</xref>
###xml 73 77 73 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Gu3">[54]</xref>
###xml 374 378 374 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Vinals1">[55]</xref>
###xml 379 383 379 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Connelly3">[56]</xref>
###xml 384 388 384 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Parathath2">[57]</xref>
###xml 445 454 445 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5A</xref>
###xml 509 518 509 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5B</xref>
###xml 685 694 685 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5C</xref>
###xml 774 783 774 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g005">Figure 5D</xref>
###xml 886 889 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Importantly, these different mutants had reduced HDL binding levels [52],[54], which could not unambiguously discriminate between altered HDL binding vs. reduced lipid transfer, the reason for loss of HDL-mediated infection-enhancement induced by SR-BI. Therefore, we next generated the N173Q and G420H-G424H mutants that have impaired lipid transfer but normal HDL binding [55],[56],[57]. These mutants induced ca. 10-fold reduced sE2 binding (Figure 5A), which resulted in ca. 4-5 fold reduced infectivity (Figure 5B). Interestingly, while the N173Q mutant poorly induced HDL-mediated infection-enhancement, the G420H-G424H failed to support stimulation of infection induced by HDL (Figure 5C), in agreement with their strongly reduced capacity to mediate lipid transfer (Figure 5D). These data further supported the notion that the lipid transfer functions of SR-BI are required for HCV entry enhancement.
###end p 45
###begin p 46
###xml 119 128 119 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s004">Figure S4</xref>
###xml 308 316 308 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g004">Figure 4</xref>
###xml 51 54 <span type="species:ncbi:10116">rat</span>
###xml 84 89 <span type="species:ncbi:9606">human</span>
These results, obtained in the background of BRL3A rat cells, were confirmed in the human background of SK-Hep1 cells (Figure S4). Furthermore, we performed HCVcc infection assays of SK-Hep1-CLDN1 cells expressing a subset of mutants of SR-BI extracellular domain (i.e., Q402R-E418R, N173Q and G420H-G424H) (Figure 4). We confirmed that these mutant receptors reduced infection in comparison to wt SR-BI, but completely abolished HDL-mediated infection enhancement.
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 178 181 178 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Scarselli1">[7]</xref>
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Maillard1">[24]</xref>
###xml 187 191 187 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Heo1">[58]</xref>
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch2">[12]</xref>
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Lavillette1">[14]</xref>
###xml 295 299 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 300 304 300 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Catanese1">[26]</xref>
###xml 305 309 305 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset1">[29]</xref>
###xml 310 314 310 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Grove1">[59]</xref>
###xml 424 428 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 429 433 429 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Catanese1">[26]</xref>
###xml 434 438 434 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux1">[27]</xref>
###xml 439 443 439 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Meunier1">[28]</xref>
###xml 444 448 444 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset1">[29]</xref>
###xml 449 453 449 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux2">[35]</xref>
###xml 559 563 559 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Nieland1">[53]</xref>
###xml 744 748 744 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 749 753 749 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset1">[29]</xref>
###xml 73 76 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 164 167 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 255 258 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 376 379 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 389 394 <span type="species:ncbi:9606">human</span>
###xml 623 626 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 734 737 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 869 872 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 959 962 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Several lines of evidence suggested that SR-BI plays a prominent role in HCV entry into cells. First, SR-BI provides both direct and ApoB-mediated interaction with HCV particles [7],[24],[58]. Second, antibody blocking or down-regulation of SR-BI inhibit HCV entry in permissive cells [12],[14],[25],[26],[29],[59]. Third, HDL, the major important ligand of SR-BI, stimulates HCV entry in human hepatocarcinoma target cells [25],[26],[27],[28],[29],[35]. Finally, using small molecules that inhibit the selective lipid transfer functions of SR-BI, named BLTs [53], it was proposed that besides providing a docking site for HCV particles, SR-BI physiological property, i.e., cholesterol uptake and/or efflux, could be exploited during HCV entry [25],[29]. Yet, despite this indirect evidence, functional complementation assays addressing the implication of SR-BI during HCV entry were lacking since no cell type in which SR-BI ectopic expression would restore HCV infection has been available.
###end p 48
###begin p 49
###xml 74 77 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 237 242 <span type="species:ncbi:9606">human</span>
###xml 251 256 <span type="species:ncbi:9606">human</span>
###xml 310 313 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 403 408 <span type="species:ncbi:9606">human</span>
###xml 436 439 <span type="species:ncbi:10116">rat</span>
###xml 459 462 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 616 619 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 670 673 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 688 693 <span type="species:ncbi:9606">human</span>
###xml 719 722 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 803 808 <span type="species:ncbi:9606">human</span>
Aiming to directly address these different possible functions of SR-BI in HCV entry, we report here for the first time a sensitive functional complementation assay that allows studying this molecule by mutagenesis. By screening cells of human and non-human origins for absence or low SR-BI expression in which HCV entry could be restored by SR-BI ectopic expression, our data highlight one non-hepatoma human cell line and one hepatoma rat cell line in which HCV entry assays could be performed. Our results therefore clearly demonstrate that SR-BI is an essential entry factor, along with CD81 and CLDN1, mediating HCV entry. This is also the first report showing that HCV can enter non-human cells upon expression of HCV receptors. Importantly, we show that the selective lipid transfer properties of human SR-BI were fully functional in such heterologous cell backgrounds, allowing us to directly address the role of specific residues of SR-BI ecto- and endo-domains in HDL-mediated infection-enhancement.
###end p 49
###begin p 50
###xml 324 327 324 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Evans1">[9]</xref>
###xml 556 560 556 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Silver1">[21]</xref>
###xml 561 565 561 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Harder1">[60]</xref>
###xml 566 570 566 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Wustner1">[61]</xref>
###xml 673 677 673 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Calvo1">[18]</xref>
###xml 763 767 763 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Webb1">[19]</xref>
###xml 768 772 768 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Eckhardt1">[47]</xref>
###xml 867 870 867 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">via</italic>
###xml 909 913 909 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Grove1">[59]</xref>
###xml 1461 1465 1457 1461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Eckhardt2">[51]</xref>
###xml 1687 1690 1683 1686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">via</italic>
###xml 4 7 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 164 167 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 450 453 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 990 993 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1110 1113 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1263 1266 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1484 1487 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1593 1596 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1657 1660 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
How HCV undergoes cell penetration following binding to its specific receptors remains ill defined. SR-BI alone or, alternatively, SR-BI interacting with the other HCV receptors may initiate cell penetration and/or mediate virus internalization. That HCVcc binds SR-BI-expressing CHO cells but not CD81-expressing CHO cells [9] may imply that a first contact with SR-BI is necessary before the viral particle can interact with CD81. SR-BI may induce HCV endocytosis by itself, as suggested by its capacity to mediate internalization of its natural ligands [21],[60],[61]. Interestingly, expression of SR-BII, a mRNA splice variant that differs from SR-BI at the C-terminus [18], which confers intracellular localization of SR-BII and rapid internalization of HDL [19],[47], reduces HCVpp entry as compared to SR-BI (this report). Along with findings of others, i.e., via SR-BII over-expression in Huh-7 cells [59], this indicates that SR-BI, rather than SR-BII, is a preferred receptor for HCV entry and that determinants of SR-BI cytoplasmic tail different from those controlling its endocytosis may regulate HCV entry. Additionally, deletion (DeltaCterm mutant) or replacement (SR-BI/CD36 chimera) of SR-BI cytoplasmic tail also reduced its capacity to mediate HCV entry. Moreover, functional restoration of the SR-BII dileucine endocytic motif in the SR-BI C-terminal cytoplasmic tail (SES mutant), which induces rapid internalization of SR-BI/HDL complexes [51], did not increase HCV entry but rather reduced it. Altogether, these results suggested that if SR-BI initiates and/or promotes HCV endocytosis, it could be through its interaction with other HCV entry factors rather than via a classical binary virus/receptor complex.
###end p 50
###begin p 51
###xml 403 407 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Ikemoto1">[49]</xref>
###xml 408 412 404 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Komori1">[50]</xref>
###xml 620 624 616 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Gu1">[46]</xref>
###xml 906 910 902 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Rhainds1">[62]</xref>
###xml 927 931 923 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Babitt1">[63]</xref>
###xml 1023 1027 1019 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Subbaiah1">[64]</xref>
###xml 1028 1032 1024 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-delaLleraMoya2">[65]</xref>
###xml 1286 1290 1282 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Marsh1">[66]</xref>
###xml 139 142 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 429 432 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 789 792 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1048 1051 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
In agreement with this assumption, our data raise the possibility that determinants of the C-terminal cytoplasmic tail contribute to SR-BI HCV entry functions through modulation of its intracellular trafficking and/or membrane localization. The study of the DeltaAKL mutant, which abrogates SR-BI interaction with PDZK1 that modulates its intracellular transport, localization, assembly and scaffolding [49],[50], did not affect HCV entry, consistent with the lack of effect of PDZK1 down-regulation in Huh-7 cells. However, as suggested by results with the 2CS mutant (C462S-C470S), which prevents SR-BI palmitoylation [46] and thus its potential association to lipid raft micro-domains, our results indicate that localization of SR-BI in specific micro-environments could play a role in HCV entry. Indeed, sub-cellular fractionation experiments showed that SR-BI localizes in plasma membrane lipid rafts [62] and/or caveolae [63], which may play a critical role in SR-BI-mediated transfer of lipids between HDL and cells [64],[65] and, possibly, HCV entry. Such low-density membrane microdomains are enriched in cholesterol and glycolipids, and have been involved in a number of transport and signaling events that could be important for virus endocytosis and intracellular transport [66].
###end p 51
###begin p 52
###xml 621 625 621 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Parathath1">[22]</xref>
###xml 626 630 626 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-KellnerWeibel1">[23]</xref>
###xml 631 635 631 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-delaLleraMoya2">[65]</xref>
###xml 678 682 678 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Zhang2">[67]</xref>
###xml 93 96 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 204 207 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 733 736 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Our study of SR-BI ectodomain mutants provides the first direct and functional evidence that HCV and HDL binding to SR-BI, and intact lipid transfer properties of SR-BI are required for SR-BI function as HCV entry factor. SR-BI-mediated uptake of HDL CE is a two-step process that requires high-affinity binding of HDL followed by incorporation of CE to the plasma membrane pool and subsequent transfer of the lipid to an inaccessible pool. CE uptake is followed by hydrolysis to free cholesterol by a neutral CE hydrolase. SR-BI-mediated lipid uptake leads to increase of cholesterol content of the target cell membrane [22],[23],[65] and activates distinct signaling pathways [67], which may provide different beneficial roles for HCV entry.
###end p 52
###begin p 53
###xml 28 36 28 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 153 157 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Lavillette2">[15]</xref>
###xml 255 259 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Stiasny1">[68]</xref>
###xml 479 483 479 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Umashankar1">[69]</xref>
###xml 514 518 514 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Rawat1">[70]</xref>
###xml 392 395 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 530 533 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
First, using liposome-based in vitro fusion assays, HCVpp membrane fusion was shown to be facilitated when cholesterol is present in the target membrane [15]. By analogy with fusion processes of Flaviviruses and Alphaviruses that have been widely studied [68], cholesterol-enrichment of target membranes may induce specific curvature that could positively influence the early interactions of HCV fusion protein. Alternatively, local cholesterol enrichment may facilitate binding [69] and/or conformational changes [70] within the HCV glycoproteins that are required for membrane fusion processes.
###end p 53
###begin p 54
###xml 78 82 78 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux1">[27]</xref>
###xml 318 322 318 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux1">[27]</xref>
###xml 376 380 376 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Meertens1">[11]</xref>
###xml 448 452 448 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Garcia1">[71]</xref>
###xml 600 604 600 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux1">[27]</xref>
###xml 935 938 935 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">via</italic>
###xml 1248 1251 1248 1251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">via</italic>
###xml 1369 1373 1369 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Zeisel1">[32]</xref>
###xml 1374 1378 1374 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Kapadia1">[72]</xref>
###xml 1449 1453 1449 1453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Kapadia1">[72]</xref>
###xml 1525 1529 1525 1529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 1530 1534 1530 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux1">[27]</xref>
###xml 1615 1625 1615 1625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Plasmodium</italic>
###xml 1697 1701 1697 1701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Yalaoui1">[73]</xref>
###xml 1712 1716 1712 1716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Rodrigues1">[74]</xref>
###xml 1891 1895 1891 1895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Yalaoui1">[73]</xref>
###xml 1987 1997 1987 1997 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Plasmodium</italic>
###xml 2016 2020 2016 2020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 2021 2025 2021 2025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Voisset1">[29]</xref>
###xml 2026 2030 2026 2030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Rodrigues1">[74]</xref>
###xml 2150 2160 2150 2160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Plasmodium</italic>
###xml 2229 2233 2229 2233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Yalaoui1">[73]</xref>
###xml 2234 2238 2234 2238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Silvie1">[75]</xref>
###xml 2273 2283 2273 2283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Plasmodium</italic>
###xml 2328 2332 2328 2332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Rodrigues1">[74]</xref>
###xml 2469 2478 2469 2478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g002">Figure 2C</xref>
###xml 2643 2652 2643 2652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s002">Figure S2</xref>
###xml 2756 2760 2756 2760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Yalaoui1">[73]</xref>
###xml 2941 2945 2941 2945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-deGrooth1">[76]</xref>
###xml 3058 3067 3058 3067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s002">Figure S2</xref>
###xml 3147 3155 3147 3155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g006">Figure 6</xref>
###xml 3457 3461 3457 3461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Reaven1">[77]</xref>
###xml 279 300 <span type="species:ncbi:11786">murine leukemia virus</span>
###xml 324 344 <span type="species:ncbi:11033">Semliki forest virus</span>
###xml 349 375 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
###xml 675 678 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 916 919 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1121 1124 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1157 1160 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1355 1358 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1399 1402 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1483 1486 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1691 1696 <span type="species:ncbi:10090">mouse</span>
###xml 1706 1711 <span type="species:ncbi:9606">human</span>
###xml 2002 2005 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 2123 2126 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 2268 2271 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 2738 2743 <span type="species:ncbi:10090">mouse</span>
###xml 2817 2822 <span type="species:ncbi:10090">mouse</span>
###xml 2827 2832 <span type="species:ncbi:9606">human</span>
###xml 3259 3262 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 3503 3506 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Second, HCVpp internalization was shown to be specifically accelerated by HDL [27]. As discussed above, this effect is likely to be indirect. Indeed, the internalization rate of HCVpp is significantly slower than that of pseudo-particles harboring the surface glycoproteins from murine leukemia virus, influenza virus [27], Semliki forest virus, or vesicular stomatitis virus [11], and has an half-life much longer than that of HDL internalization [71]. Furthermore, HDL added during the initial stage of infection suppresses an one-hour time lag during which cell-bound virions are not internalized [27]. This may reflect the time interval required to assemble a functional HCV receptor complex, which may be reduced upon SR-BI activation through modifications of the cell membrane. A possibility is that HDL/SR-BI interaction augments the rate of CD81 recruitment at virion-binding sites and/or internalization of HCV/CD81 complexes via a cholesterol-dependent pathway. In agreement with this assumption, that SR-BI mutants increasing internalization (SR-BII and SES mutant) are less effective than wt SR-BI to mediate HCV entry (see above) suggests that HCV internalization is likely driven by SR-BI interacting with other receptors rather than via SR-BI alone. In this respect, it is interesting that CD81 and SR-BI function cooperatively to initiate HCV infection [32],[72], that CD81-mediated HCV entry seems dependent on membrane cholesterol [72], and that SR-BI/HDL-mediated HCV entry enhancement still requires CD81 [25],[27]. Interestingly, both SR-BI and CD81 have been proposed as cell factors allowing Plasmodium sporozoite invasion and/or intracellular parasite development in mouse [73] and human [74] hepatocytes, perhaps through SR-BI-induced regulation of the organization of CD81 at the plasma membrane by mediating an arrangement permissive to penetration by sporozoites [73]. Yet, although SR-BI lipid transfer blockers, i.e., SR-BI antibodies and BLTs, reduce both Plasmodium and HCV infection [25],[29],[74], there seems to be important differences in the mechanisms involved. Indeed, in contrast to HCV surface glycoproteins, Plasmodium sporozoites do not seem to directly interact with SR-BI and/or CD81 [73],[75]. Furthermore, in contrast to HCV, Plasmodium sporozoites invasion is not enhanced by HDL [74]. Finally, while we demonstrated that cholesterol uptake mediated by SR-BI ectopically expressed in BRL3A-CD81-CLN1 cells is functional (Figure 2C), we did not notice up-regulation of CD81 cell surface expression and TEM localization whether these cells expressed or not SR-BI and following treatment with HDL (Figure S2 and data not shown), in contrast to other studies that revealed such CD81 changes in mouse hepatocytes [73]. These differences may reflect dissimilar properties of mouse vs. human SR-BI and CD81, of species-specific cholesterol transport processes and/or of the cellular backgrounds used [76]. Likewise, no CD81 changes could be detected in Huh-7 cells incubated in the presence or in the absence of HDL (Figure S2). Consistently, HDL did not enhance sE2 binding capacity to SR-BI and/or CD81 (Figure 6). Finally, recent results of others suggest that the association of CD81 with TEM is not essential for HCV entry (Dr Jean Dubuisson, Personal Communication). Alternatively, homo-oligomerization of SR-BI seems associated with functional expression of the selective HDL cholesteryl ester uptake pathway [77] and may contribute to the formation of a HCV receptor complex.
###end p 54
###begin p 55
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Meunier1">[28]</xref>
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux2">[35]</xref>
###xml 360 363 360 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">via</italic>
###xml 408 412 408 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux2">[35]</xref>
###xml 102 105 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 241 244 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 312 315 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Third, an essential component of HDL that seems responsible for infection enhancement at the level of HCV membrane fusion is the apolipoprotein C-I (ApoC-I) [28],[35], an exchangeable apolipoprotein that could be transferred from HDL to the HCV membrane during SR-BI-mediated lipid transfer and could predispose HCV envelope for fusion with a target membrane, via alterations of its outer phospholipid layer [35].
###end p 55
###begin p 56
###xml 329 336 329 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 24 27 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 53 56 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 285 288 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Further analysis of the HCV entry events mediated by HCV receptors and co-factors will be greatly facilitated by the availability of the novel functional receptor-complementation assay described in this report. Moreover, it opens the way to develop small animal models susceptible for HCV in which entry inhibitors can be tested in vivo.
###end p 56
###begin title 57
Materials and Methods
###end title 57
###begin title 58
Cell lines
###end title 58
###begin p 59
###xml 6 10 6 10 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Nakabayashi1">[78]</xref>
###xml 294 298 294 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Catalano1">[79]</xref>
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 60 65 <span type="species:ncbi:9606">human</span>
###xml 113 116 <span type="species:ncbi:10116">rat</span>
###xml 236 242 <span type="species:ncbi:9913">bovine</span>
###xml 275 278 <span type="species:ncbi:10116">rat</span>
###xml 373 377 <span type="species:ncbi:9913">calf</span>
Huh-7 [78], PLC/PRF/5 human hepatoma (ATCC CRL-8024), Hep3B human hepatocellular carcinoma (ATCC HB-8064), BRL3A rat hepatocytes (ATCC CRL-1442) and 293T (ATCC CRL-1573) cells were grown in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Invitrogen). Fu5AH rat hepatoma cells [79] were grown in Eagle's MEM supplemented with 1% L-glutamine and 5% newborn calf serum. CHO (ATCC CRL-1582) and SK-Hep1 (ATCC HTB-52) cells were maintained in RPMI (Invitrogen) with 10% FBS.
###end p 59
###begin title 60
Expression constructs and establishment of cells lines expressing CLDN1, CD81, and SR-BI wt/mutants
###end title 60
###begin p 61
###xml 418 422 418 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Oquendo1">[80]</xref>
###xml 459 463 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Calvo1">[18]</xref>
###xml 475 479 475 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Eckhardt1">[47]</xref>
###xml 480 484 480 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Mulcahy1">[48]</xref>
###xml 536 540 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Calvo1">[18]</xref>
###xml 603 607 603 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Connelly1">[44]</xref>
###xml 608 612 608 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Connelly2">[45]</xref>
###xml 613 617 613 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Gu1">[46]</xref>
###xml 634 638 630 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Connelly2">[45]</xref>
###xml 649 653 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Ikemoto1">[49]</xref>
###xml 659 663 651 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Eckhardt2">[51]</xref>
###xml 929 933 921 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Gu1">[46]</xref>
###xml 934 938 926 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Gu2">[52]</xref>
###xml 939 943 931 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Gu3">[54]</xref>
###xml 944 948 936 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Vinals1">[55]</xref>
###xml 949 953 941 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Connelly3">[56]</xref>
###xml 954 958 946 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Parathath2">[57]</xref>
###xml 1364 1368 1356 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Sandrin1">[81]</xref>
###xml 1369 1373 1361 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Ngre1">[82]</xref>
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 173 194 <span type="species:ncbi:11786">murine leukemia virus</span>
###xml 524 529 <span type="species:ncbi:9606">human</span>
###xml 755 760 <span type="species:ncbi:9606">human</span>
###xml 1020 1025 <span type="species:ncbi:9606">human</span>
Retroviral vectors expressing human CD81 (GenBank accession number: NM_004356), Claudin-1 (NM_021101) and SR-BI (Z22555) or mutant SR-BI receptors were inserted in CNC MLV (murine leukemia virus) vector backbones (kind gift of M. Collins) harboring selectable marker genes for blasticidin, neomycin and hygromycin respectively. Construct details are available upon request. The CD36 was kindly provided by Brian Seeds [80]. The cDNAs encoding the SR-BI-Short [18] and SR-BII [47],[48] were based on the original sequence of human SR-BI [18] and were inserted in the CNC expression vector. The SRBI-CD36 [44],[45],[46], the DeltaCterm [45], DeltaAKL [49], SES [51] chimeras were previously described for rodent SR-BI and were used to derive the equivalent human SR-BI chimeras investigated in this work. Point mutants encoding the following SR-BI receptors: M159R, N173G, Q402R, E418R, Q402R-E418R, G420H-G424H, C462S-C470S (2CS) [46],[52],[54],[55],[56],[57] and E210G (MD and FLC, unpublished data), were introduced in human SR-BI cDNA by site directed mutagenesis (primer sequences are available upon request). All mutants were sequenced to ensure that the clones possessed only the expected mutation. Retroviral vectors containing CD81, CLDN1 and wt or mutant SR-BI receptors were produced from 293T cells as VSV-G-pseudotyped particles as described previously [81],[82]. Stable expression of either receptor in target cells was obtained by transduction with vector particle-containing supernatants of 293T producer cells, followed by antibiotic selection.
###end p 61
###begin title 62
###xml 24 27 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Production of HCVpp and HCV entry assays
###end title 62
###begin p 63
###xml 103 107 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch4">[33]</xref>
###xml 256 260 256 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch4">[33]</xref>
###xml 52 55 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 187 190 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The expression vector for the E1E2 glycoproteins of HCV strain H77 (AF009606) was described previously [33]. Viral pseudo-particles named HCVpp and VSV-Gpp harboured the glycoproteins of HCV and VSV, respectively, and were produced as described previously [33] by transfection in 293T cells of vectors encoding viral glycoproteins, packaging proteins, and GFP-transfer vector. Prior to harvest viral particles-containing supernatants, producer cells were incubated in DMEM containing 0.1% FCS for 24 hrs.
###end p 63
###begin p 64
###xml 547 551 543 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch4">[33]</xref>
###xml 762 763 758 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 770 771 766 767 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
For infection assays, target cells were seeded 24 hr prior to inoculation. 2 hr prior to infection, target cells were pre-incubated in DMEM containing 0.1% FCS. Then medium was removed and dilutions of viral supernatants were added to the cells and incubated for 4 hr. Where indicated, HDL (Calbiochem) was added to the infection reactions at 6 microg/ml of cholesterol. Supernatants were then removed and the infected cells kept in regular medium (DMEM, 10% FCS) for 72 hr before analysis of the percentage of GFP-positive cells by FACS analysis [33]. The infectious titers were expressed as GFP infection units (i.u.) per ml of HCVpp-containing medium. Infections were controlled by using non-enveloped particles, which resulted in background titers between 102 and 103 GFP i.u./ml.
###end p 64
###begin title 65
Production of HCVcc and infection assays
###end title 65
###begin p 66
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Delgrange1">[83]</xref>
###xml 115 123 115 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Plasmid pJFH-1 displaying previously described mutations F172C and P173S in core, as well as N534K in E2 [83], was in vitro transcribed using the Megascript T7 kit (Ambion). After DNAse treatment, genomic RNA was purified by two acidic phenol/chloroform extractions and pelleted by isopropanol precipitation. Then, RNA was electroporated into Huh-7.5 cells using Gene Pulser II apparatus (Biorad) and cells were cultured under standard conditions. Virus-containing medium was harvested, pooled and added to target cells as described above. Where indicated, HDL (Calbiochem) was added to the infection reactions at 0.6 microg/ml of cholesterol.
###end p 66
###begin p 67
###xml 179 202 179 202 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CTTCACGCAGAAAGCGTCTA</named-content>
###xml 207 230 207 230 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CAAGCACCCTATCAGGCAGT</named-content>
###xml 302 325 302 325 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCCGAGACTATCTGCACTAC</named-content>
###xml 330 353 330 353 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ATGTCCAGCCTCAGAACTTC</named-content>
###xml 384 407 384 407 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTTACCAGGGCTGCCTTCTC</named-content>
###xml 412 434 412 434 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGGTTTCCCGTTGATGACC</named-content>
###xml 165 168 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 358 361 <span type="species:ncbi:10116">rat</span>
Infected cells were collected by trypsinization, and RNA was prepared (RNeasy; QIAGEN), reverse transcribed (iScript cDNA synthesis kit, Biorad) and quantified with HCV specific (5'-CTTCACGCAGAAAGCGTCTA and 5'-CAAGCACCCTATCAGGCAGT) and house-keeping primers targeting RSP11 in SK-Hep1 and Huh-7 cells (5'-GCCGAGACTATCTGCACTAC and 5'-ATGTCCAGCCTCAGAACTTC) or rat GAPDH in BRL3A cells (5'-GTTACCAGGGCTGCCTTCTC and 5'-GGGTTTCCCGTTGATGACC) using the Platinum SYR Green qPCR super mix kit from Invitrogen on an Applied 7000 apparatus.
###end p 67
###begin title 68
Binding and surface staining assays
###end title 68
###begin p 69
###xml 98 102 98 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Dreux1">[27]</xref>
###xml 103 107 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Flint1">[38]</xref>
###xml 202 203 192 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 393 398 <span type="species:ncbi:10090">mouse</span>
Binding of soluble E2 glycoprotein, derived from the H77-E2 was performed as previously described [27],[38]. Briefly, 5 microg/ml of sE2 harbouring a His-tag was incubated for 1 hr at 37degreesC with 106 target cells. The amount of cell-bound sE2 was determined by FACS analysis using 2 microg/ml of an anti-His tag antibody (pentaHis, Qiagen) and using Allophycocyanine (APC)-conjugated anti-mouse antibodies.
###end p 69
###begin p 70
###xml 82 83 82 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 350 355 <span type="species:ncbi:10090">mouse</span>
The surface expression of hCD81 and hSR-BI was quantified by FACS analysis from 106 live cells using anti-CD81 mAb (clone JS81, Pharmingen) and anti-SR-BI mAb (CLA-1, BD Biosciences), respectively, added to cells for 1 hr in PBFA at 4degreesC. After washing, the binding of antibody to the cell surface was detected using RPE- or APC-conjugated anti-mouse antibodies.
###end p 70
###begin title 71
Lipid transfer assays
###end title 71
###begin p 72
###xml 59 63 59 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-delaLleraMoya1">[37]</xref>
###xml 118 119 118 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 245 249 <span type="species:ncbi:9913">calf</span>
###xml 281 287 <span type="species:ncbi:9913">bovine</span>
Lipid efflux assays were performed as previously described [37]. After plating, cells were labeled by incubation with 3H-cholesterol (1 microCi/ml) for 48 hr. Subsequently cells were incubated for 24 hr in the presence of BSA (0.5%) and newborn calf serum (25%) for Fu5AH or fetal bovine serum (25%) for BRL3a or SK-Hep1, to allow equilibration of the label. After equilibration, cholesterol acceptors (20 microg phospholipid/ml of isolated HDL) were added in serum-free medium and incubated with cells for 4 hr at 37degreesC. Fractional cholesterol efflux (expressed as percentage) was calculated as the amount of the label recovered in the medium divided by the total label in each well (radioactivity in the medium+radioactivity in the cells) obtained after lipid extraction from cells in a mixture of 3:2 hexane-isopropanol (3:2 v/v). The background cholesterol efflux obtained in the absence of cholesterol acceptor was subtracted from the efflux values obtained with the test samples.
###end p 72
###begin p 73
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-LeGoff1">[36]</xref>
###xml 142 143 142 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 302 303 302 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
Selective HDL-CE (cholesteryl ester) uptake was performed as previously described [36]. Cells were plated in 24-well tissue culture plates (106 cells/well). Two days after plating, cells were washed 3 times with PBS and once with serum-free medium. Cells were subsequently incubated in the presence of 3H-CE-labelled HDL (60 microg protein) diluted in serum-free medium at 37degreesC for 5 hr. At the end of incubation, the medium was removed and cells were washed 4 times with PBS and incubated in the presence of an excess of unlabelled HDL (100 microg protein) for 30 minutes. Cells were then washed 4 times with PBS and solubilized with 200 microl of NaOH 0.2 N for 15 minutes at room temperature with gentle mixing. Protein content (20 microl) from each well was measured using the Bicinchoninic acid protein reagent (Pierce). The radioactive content of 100 microl of each cell lysate was measured by liquid scintillation counting. Selective uptake was calculated from the known specific radioactivity of radiolabelled HDL-CE and is expressed in microg HDL-CE/microg cell protein.
###end p 73
###begin title 74
Supporting Information
###end title 74
###begin p 75
###xml 1045 1056 1042 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000310.s005">Protocol S1</xref>
###xml 1581 1585 1578 1582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Lavillette2">[15]</xref>
###xml 1772 1773 1769 1770 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 2381 2382 2374 2375 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 2450 2451 2443 2444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 2734 2738 2723 2727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
###xml 104 107 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 227 230 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 313 318 <span type="species:ncbi:10090">mouse</span>
###xml 373 376 <span type="species:ncbi:10116">rat</span>
###xml 436 439 <span type="species:ncbi:10116">rat</span>
###xml 641 646 <span type="species:ncbi:10090">mouse</span>
###xml 796 799 <span type="species:ncbi:10116">rat</span>
###xml 817 822 <span type="species:ncbi:9606">human</span>
###xml 1013 1016 <span type="species:ncbi:10116">rat</span>
###xml 1248 1251 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1339 1342 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1822 1825 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1930 1933 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1950 1953 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
HCVpp entry in receptor-complemented BRL3A or SK-Hep1 cells. (A) Western blot analysis of the indicated HCV receptors in lysates of BRL3A, SK-Hep1, and Huh-7 cells ectopically expressing (+) or not expressing (-) the indicated HCV receptors using SR-BI (CLA-1, BD Bioscience), CD81 (JS81, Pharmingen), and CLDN1 (mouse anti-Claudin-1, Interchim) antibodies. The endogenous rat orthologs of these molecules were detected in BRL3A, Fu5AH rat hepatoma cells, and Huh-7 cells (Huh-7*, Fu5AH*, and BRL3A*) by Western blot analysis using cross-reactive antibodies against SR-BI (400-104, Novus), CD81 (EAT-2, Santa Cruz Biotechnology), and CLDN1 (mouse anti-Claudin-1, Interchim) antibodies. The actin staining (mAb AC74, Sigma-Aldrich) was used to ensure equal input of cell lysates. (B) Abundance of rat (white bars) and human (black bars) SR-BI mRNA levels in Fu5AH, BRL3A, BRL3A-CD81-CLDN1, and BRL3A-CD81-CLDN1-SR-BI cells. Total RNA was then extracted, quantified by Real time quantitative PCR, and normalized to rat beta-Gus housekeeping gene (Protocol S1). Expression data were corrected for PCR efficiencies of the target and the reference gene, thus making possible analysis of the expression of one gene relative to the others. (C) Results of HCV entry assays on BRL3A-CD81-CLDN1-SR-BI, BRL3A-CD81-CLDN1, and Huh-7 target cells using HCV pseudo-particles carrying a luciferase marker gene and harboring E1E2 glycoproteins derived from the indicated genotypes/subtypes 1a (H77), 1b (Con-1, UKN1B 12.16), 2a (JFH-1, UKN2A 2.4), 2b (UKN2B 2.8), and 3a (UKN3A 1.28), as indicated [15], control viral particles harboring the VSV-G glycoprotein (diluted 1/100) or no glycoprotein (noENV). Results display average infectious titers, expressed as Luciferase unit (RLU) per 105 target cells (mean+/-SD; n = 3). (D) Results of HCV entry assays on BRL3A (left panel) and SK-Hep1 (right panel) cells ectopically expressing the indicated HCV receptors using HCV pseudo-particles harboring H77-E1E2 glycoproteins (HCVpp), control viral particles harboring the VSV-G glycoprotein (VSV-Gpp), or no glycoprotein (noENVpp). The viral particles, containing a GFP marker gene, were produced in cell culture media devoid of serum lipoproteins. Results are expressed as percentages of the infectious titers (mean+/-SD; n = 3) determined in BRL3A cells expressing CD81, CLDN1, and SR-BI (titer: 2x104 i.u./ml) and SK-Hep1 expressing CD81, CLDN1, and SR-BI (titer: 5x104 i.u./ml). As indicated, HCVpp entry assays were performed in the absence (-) or in the presence (HDL) of 6 microg/ml cholesterol-HDL. No changes of infectivity with VSV-Gpp control particles were detected under these experimental conditions (data not shown), as reported previously [25].
###end p 75
###begin p 76
(0.19 MB TIF)
###end p 76
###begin p 77
Click here for additional data file.
###end p 77
###begin p 78
Cell surface expression of hCD81 and/or hSR-BI in BRL3A cells. BRL3A cells expressing the indicated entry factors were pre-incubated for 2 hrs in low serum-containing medium (0.1%), then incubated for 1 hr at 37degreesC in the absence (black lines) or in the presence (gray lines) of HDL (6 microg/ml cholesterol-HDL) before staining with JS81 (left panels) or CLA-1 (right panels) antibodies. The background of fluorescence was provided by staining the cells with the secondary antibodies only (dotted lines).
###end p 78
###begin p 79
(0.37 MB TIF)
###end p 79
###begin p 80
Click here for additional data file.
###end p 80
###begin p 81
###xml 165 188 165 188 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCTATGGCTTTCACTTAAAT</named-content>
###xml 202 224 202 224 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GAAAGAAGGCCTATGATTA</named-content>
###xml 257 261 257 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Qin1">[84]</xref>
###xml 390 411 390 411 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AAGTGCTTGGAAGACGAT</named-content>
###xml 423 445 423 445 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GATCGATGACCTCTTCTCC</named-content>
###xml 0 3 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 571 577 <span type="species:ncbi:9986">rabbit</span>
###xml 718 721 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 791 794 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
HCV entry in PDZK1 down-regulated target cells. PDZK1 (GenBank accession number: NM_002614) down-regulation was induced upon expression of specific shRNAs (PDZK1-1: 5'-GCTATGGCTTTCACTTAAAT and PDZK1-2: 5'-GAAAGAAGGCCTATGATTA) via the FG12 lentiviral vector [84] introduced in Huh-7 target cells. As controls, Huh-7 cells were transduced with FG12-derived vectors carrying shRNAs for CLDN1 (5'-AAGTGCTTGGAAGACGAT) and CD81 (5'-GATCGATGACCTCTTCTCC) or were left intact (-). (A) Western blot analysis of PDZK1 in lysates of Huh-7 cells in which these shRNAs were expressed (rabbit polyclonal Ab NB 400-1491, Novus Biologicals). The actin staining (mAb AC74, Sigma-Aldrich) was used to assess cell density. (B) Results of HCV entry assays on Huh-7 cells expressing PDZK1 or control shRNAs using HCV pseudo-particles harboring H77-E1E2 glycoproteins (HCVpp), control viral particles harboring the RD114 glycoprotein (RD114pp), or no glycoprotein (noENVpp). The viral particles, containing a CD90 marker gene, were produced in cell culture media devoid of serum lipoproteins. The results of infectivity (mean+/-SD; n = 3) are expressed relative to the infectious titers of HCVpp or of control RD114pp determined on intact Huh-7 cells, which were determined 72 hr after infection by measuring CD90 reporter gene expression by FACS analysis using an allophycocyanin (APC)-conjugated anti-CD90 mAb (clone 5E10, BD Pharmingen). As indicated, HCVpp entry assays were performed in the absence (-) or in the presence (HDL) of 6 microg/ml cholesterol-HDL.
###end p 81
###begin p 82
(0.09 MB TIF)
###end p 82
###begin p 83
Click here for additional data file.
###end p 83
###begin p 84
###xml 610 619 608 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000310-g001">Figure 1A</xref>
###xml 1259 1260 1255 1256 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1636 1640 1626 1630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000310-Bartosch3">[25]</xref>
HCVpp entry in SK-Hep1-CLDN1 cells expressing SR-BI mutants. (A) Cell surface expression (white bars) of SR-BI mutants/isoforms as determined using anti-SR-BI antibody (CLA-1, BD Bioscience). The results of cell surface expression, analyzed by flow cytometry of SK-Hep1-CLDN1 cells transduced with retroviral vectors carrying the indicated SR-BI mutants, are expressed as the average percentages of GEOmean (geometric mean) fluorescence shifts (mean+/-SD; n = 3) detected between mutant receptor-expressing cells and parental (-) cells, relative to cells expressing wild-type SR-BI (ca. 40-fold GEOmean shift, Figure 1A) set to 100. Cell surface expression of CD36 (*, data not shown) was verified using a CD36 antibody (FA6-152, abcam). Cell surface expression of SR-BI-Short (*, data not shown) was verified by immuno-blotting using an antibody against SR-BI C-terminus (400-104, Novus) on surface-biotinylated proteins that were purified with streptavidin-coated beads. (B) Effect of SR-BI mutations on infectivity of HCVpp produced in serum-free media. The results of infectivity (mean+/-SD; n = 5) are expressed relative to the infectious titers of HCVpp or of control VSV-Gpp particles determined on wt SR-BI-expressing SK-Hep1-CLDN1 cells (input ca. 104 GFP iu), set to 100. (C) Results of HCVpp infection-enhancement induced by HDL (6 microg/ml cholesterol-HDL), expressed as ratios between average infectious titers determined in the presence or absence of HDL (mean+/-SD; n = 5). No changes of infectivity of VSV-Gpp control particles were detected under these experimental conditions (data not shown), as reported previously [25].
###end p 84
###begin p 85
(0.13 MB TIF)
###end p 85
###begin p 86
Click here for additional data file.
###end p 86
###begin p 87
Supplementary Materials and Methods
###end p 87
###begin p 88
(0.03 MB DOC)
###end p 88
###begin p 89
Click here for additional data file.
###end p 89
###begin p 90
###xml 70 74 <span type="species:ncbi:4530">Rice</span>
We are grateful to T. Wakita for the gift of the JFH-1 isolate and C. Rice for the gift of the Huh-7.5 cell line. We thank F. V. Chisari for the gift of BILN2061 and 2'-C-methyl-adenosine, for sharing reagents, and for encouragement. We thank E. Rubinstein for helpful discussions, and J. Dubuisson and L. Coquerel for sharing unpublished results. We are grateful to Ophelia Granio, Maud Michelet, and Baptiste Jammart for excellent technical assistance, and to our co-workers and colleagues for encouragement and advice. We are grateful to Brian Boyd, Pablo Gastaminza, and Stefan Wieland (Scripps Research Institute, La Jolla, California) for helpful discussion and technical advice. The flow cytometry and RT-qPCR analyses were performed at the Cytometry and Genetic Analysis facilities, IFR 128 Biosciences Lyon-Gerland (France).
###end p 90
###begin title 91
References
###end title 91
###begin article-title 92
###xml 23 40 <span type="species:ncbi:11103">hepatitis C virus</span>
Global epidemiology of hepatitis C virus infection.
###end article-title 92
###begin article-title 93
###xml 14 31 <span type="species:ncbi:11103">hepatitis C virus</span>
Cell entry of hepatitis C virus.
###end article-title 93
###begin article-title 94
###xml 19 36 <span type="species:ncbi:11103">hepatitis C virus</span>
Early steps of the hepatitis C virus life cycle.
###end article-title 94
###begin article-title 95
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus entry.
###end article-title 95
###begin article-title 96
###xml 15 32 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 36 41 <span type="species:ncbi:9606">human</span>
Association of hepatitis C virus in human sera with beta-lipoprotein.
###end article-title 96
###begin article-title 97
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.
###end article-title 97
###begin article-title 98
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 82 99 <span type="species:ncbi:11103">hepatitis C virus</span>
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.
###end article-title 98
###begin article-title 99
###xml 11 28 <span type="species:ncbi:11103">hepatitis C virus</span>
Binding of hepatitis C virus to CD81.
###end article-title 99
###begin article-title 100
###xml 15 32 <span type="species:ncbi:11103">hepatitis C virus</span>
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.
###end article-title 100
###begin article-title 101
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus entry depends on clathrin-mediated endocytosis.
###end article-title 101
###begin article-title 102
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles.
###end article-title 102
###begin article-title 103
###xml 14 31 <span type="species:ncbi:11103">hepatitis C virus</span>
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.
###end article-title 103
###begin article-title 104
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.
###end article-title 104
###begin article-title 105
###xml 60 77 <span type="species:ncbi:11103">hepatitis C virus</span>
Characterization of host-range and cell entry properties of hepatitis C virus of major genotypes and subtypes.
###end article-title 105
###begin article-title 106
###xml 0 11 <span type="species:ncbi:11103">Hepatitis C</span>
Hepatitis C Virus Glycoproteins Mediate Low pH-dependent Membrane Fusion with Liposomes.
###end article-title 106
###begin article-title 107
###xml 46 63 <span type="species:ncbi:11103">hepatitis C virus</span>
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry.
###end article-title 107
###begin article-title 108
Virus membrane-fusion proteins: more than one way to make a hairpin.
###end article-title 108
###begin article-title 109
Identification, primary structure, and distribution of CLA-1, a novel member of the CD36/LIMPII gene family.
###end article-title 109
###begin article-title 110
SR-BII, an isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells.
###end article-title 110
###begin article-title 111
Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems.
###end article-title 111
###begin article-title 112
High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion.
###end article-title 112
###begin article-title 113
Changes in plasma membrane properties and phosphatidylcholine subspecies of insect Sf9 cells due to expression of scavenger receptor class B, type I, and CD36.
###end article-title 113
###begin article-title 114
Expression of scavenger receptor BI in COS-7 cells alters cholesterol content and distribution.
###end article-title 114
###begin article-title 115
###xml 27 44 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 50 55 <span type="species:ncbi:9606">human</span>
The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins.
###end article-title 115
###begin article-title 116
###xml 51 68 <span type="species:ncbi:11103">hepatitis C virus</span>
An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.
###end article-title 116
###begin article-title 117
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 101 118 <span type="species:ncbi:11103">hepatitis C virus</span>
High avidity monoclonal antibodies against human scavenger receptor class B type I efficiently block hepatitis C virus infection in the presence of HDL.
###end article-title 117
###begin article-title 118
###xml 34 51 <span type="species:ncbi:11103">hepatitis C virus</span>
High density lipoprotein inhibits hepatitis C virus neutralising antibodies by stimulating cell entry via activation of the scavenger receptor BI.
###end article-title 118
###begin article-title 119
###xml 46 63 <span type="species:ncbi:11103">hepatitis C virus</span>
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1.
###end article-title 119
###begin article-title 120
###xml 37 54 <span type="species:ncbi:11103">hepatitis C virus</span>
High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I.
###end article-title 120
###begin article-title 121
###xml 60 77 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 79 82 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 93 100 <span type="species:ncbi:9606">patient</span>
###xml 125 128 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry.
###end article-title 121
###begin article-title 122
###xml 29 46 <span type="species:ncbi:11103">hepatitis C virus</span>
Cellular cofactors affecting hepatitis C virus infection and replication.
###end article-title 122
###begin article-title 123
###xml 59 76 <span type="species:ncbi:11103">hepatitis C virus</span>
Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81.
###end article-title 123
###begin article-title 124
###xml 11 28 <span type="species:ncbi:11103">hepatitis C virus</span>
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes.
###end article-title 124
###begin article-title 125
###xml 42 59 <span type="species:ncbi:11103">hepatitis C virus</span>
Oxidized low density lipoprotein inhibits hepatitis C virus cell entry.
###end article-title 125
###begin article-title 126
###xml 67 84 <span type="species:ncbi:11103">hepatitis C virus</span>
The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus.
###end article-title 126
###begin article-title 127
Reevaluation of the role of the multidrug-resistant P-glycoprotein in cellular cholesterol homeostasis.
###end article-title 127
###begin article-title 128
###xml 36 41 <span type="species:ncbi:9606">human</span>
A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer.
###end article-title 128
###begin article-title 129
###xml 20 37 <span type="species:ncbi:11103">hepatitis C virus</span>
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.
###end article-title 129
###begin article-title 130
###xml 76 93 <span type="species:ncbi:11103">hepatitis C virus</span>
Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding.
###end article-title 130
###begin article-title 131
###xml 23 40 <span type="species:ncbi:11103">hepatitis C virus</span>
Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2.
###end article-title 131
###begin article-title 132
###xml 21 38 <span type="species:ncbi:11103">hepatitis C virus</span>
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.
###end article-title 132
###begin article-title 133
###xml 53 70 <span type="species:ncbi:11103">hepatitis C virus</span>
Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry.
###end article-title 133
###begin article-title 134
###xml 158 175 <span type="species:ncbi:11103">hepatitis C virus</span>
Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus.
###end article-title 134
###begin article-title 135
Comparison of class B scavenger receptors, CD36 and scavenger receptor BI (SR-BI), shows that both receptors mediate high density lipoprotein-cholesteryl ester selective uptake but SR-BI exhibits a unique enhancement of cholesteryl ester uptake.
###end article-title 135
###begin article-title 136
Analysis of chimeric receptors shows that multiple distinct functional activities of scavenger receptor, class B, type I (SR-BI), are localized to the extracellular receptor domain.
###end article-title 136
###begin article-title 137
The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain.
###end article-title 137
###begin article-title 138
High density lipoprotein uptake by scavenger receptor SR-BII.
###end article-title 138
###begin article-title 139
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human scavenger receptor class B type II (SR-BII) and cellular cholesterol efflux.
###end article-title 139
###begin article-title 140
Identification of a PDZ-domain-containing protein that interacts with the scavenger receptor class B type I.
###end article-title 140
###begin article-title 141
###xml 26 31 <span type="species:ncbi:9606">Human</span>
###xml 41 47 <span type="species:ncbi:10090">Murine</span>
Coexpression of CLA-1 and Human PDZK1 in Murine Liver Modulates HDL Cholesterol Metabolism.
###end article-title 141
###begin article-title 142
High density lipoprotein endocytosis by scavenger receptor SR-BII is clathrin-dependent and requires a carboxyl-terminal dileucine motif.
###end article-title 142
###begin article-title 143
Scavenger receptor class B, type I-mediated [3H]cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor.
###end article-title 143
###begin article-title 144
Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI.
###end article-title 144
###begin article-title 145
###xml 95 101 <span type="species:ncbi:10090">murine</span>
Dissociation of the high density lipoprotein and low density lipoprotein binding activities of murine scavenger receptor class B type I (mSR-BI) using retrovirus library-based activity dissection.
###end article-title 145
###begin article-title 146
Identification of the N-linked glycosylation sites on the high density lipoprotein (HDL) receptor SR-BI and assessment of their effects on HDL binding and selective lipid uptake.
###end article-title 146
###begin article-title 147
Separation of lipid transport functions by mutations in the extracellular domain of scavenger receptor class B, type I.
###end article-title 147
###begin article-title 148
Glycine 420 near the C-terminal transmembrane domain of SR-BI is critical for proper delivery and metabolism of high density lipoprotein cholesteryl ester.
###end article-title 148
###begin article-title 149
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 35 40 <span type="species:ncbi:9606">human</span>
Hepatitis C virus E2 links soluble human CD81 and SR-B1 protein.
###end article-title 149
###begin article-title 150
###xml 57 74 <span type="species:ncbi:11103">hepatitis C virus</span>
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity.
###end article-title 150
###begin article-title 151
Hepatic SR-BI-mediated cholesteryl ester selective uptake occurs with unaltered efficiency in the absence of cellular energy.
###end article-title 151
###begin article-title 152
Different transport routes for high density lipoprotein and its associated free sterol in polarized hepatic cells.
###end article-title 152
###begin article-title 153
Localization and regulation of SR-BI in membrane rafts of HepG2 cells.
###end article-title 153
###begin article-title 154
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae.
###end article-title 154
###begin article-title 155
Regulation of the selective uptake of cholesteryl esters from high density lipoproteins by sphingomyelin.
###end article-title 155
###begin article-title 156
Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface.
###end article-title 156
###begin article-title 157
###xml 18 24 <span type="species:ncbi:4182">sesame</span>
Virus entry: open sesame.
###end article-title 157
###begin article-title 158
###xml 55 70 <span type="species:ncbi:10029">Chinese hamster</span>
Regulation of SR-BI-mediated selective lipid uptake in Chinese hamster ovary-derived cells by protein kinase signaling pathways.
###end article-title 158
###begin article-title 159
###xml 68 97 <span type="species:ncbi:11084">tick-borne encephalitis virus</span>
Effect of membrane curvature-modifying lipids on membrane fusion by tick-borne encephalitis virus.
###end article-title 159
###begin article-title 160
Differential cholesterol binding by class II fusion proteins determines membrane fusion properties.
###end article-title 160
###begin article-title 161
Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review).
###end article-title 161
###begin article-title 162
###xml 71 76 <span type="species:ncbi:9606">human</span>
High-density lipoprotein 3 receptor-dependent endocytosis pathway in a human hepatoma cell line (HepG2).
###end article-title 162
###begin article-title 163
###xml 14 17 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Initiation of HCV Infection is Dependent on Cholesterol and Cooperativity Between CD81 and Scavenger Receptor B Type I.
###end article-title 163
###begin article-title 164
Scavenger receptor BI boosts hepatocyte permissiveness to Plasmodium infection.
###end article-title 164
###begin article-title 165
Host scavenger receptor SR-BI plays a dual role in the establishment of malaria parasite liver infection.
###end article-title 165
###begin article-title 166
###xml 32 53 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 58 75 <span type="species:ncbi:5861">Plasmodium yoelii</span>
Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity.
###end article-title 166
###begin article-title 167
A review of CETP and its relation to atherosclerosis.
###end article-title 167
###begin article-title 168
Dimerization of the scavenger receptor class B type I: formation, function, and localization in diverse cells and tissues.
###end article-title 168
###begin article-title 169
###xml 10 15 <span type="species:ncbi:9606">human</span>
Growth of human hepatoma cells lines with differentiated functions in chemically defined medium.
###end article-title 169
###begin article-title 170
Cellular SR-BI and ABCA1-mediated cholesterol efflux are gender-specific in healthy subjects.
###end article-title 170
###begin article-title 171
###xml 40 61 <span type="species:ncbi:5833">Plasmodium falciparum</span>
CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes.
###end article-title 171
###begin article-title 172
###xml 187 192 <span type="species:ncbi:9606">human</span>
###xml 201 206 <span type="species:ncbi:9606">human</span>
Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and non-human primates.
###end article-title 172
###begin article-title 173
###xml 63 92 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 139 144 <span type="species:ncbi:9606">human</span>
Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells.
###end article-title 173
###begin article-title 174
###xml 91 108 <span type="species:ncbi:11103">hepatitis C virus</span>
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins.
###end article-title 174
###begin article-title 175
###xml 11 16 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 30 35 <span type="species:ncbi:9606">human</span>
Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.
###end article-title 175
###begin p 176
The authors have declared that no competing interests exist.
###end p 176
###begin p 177
This work was supported by INSERM, ENS Lyon, CNRS, and UCB Lyon-I, and by grants from the European Union (LSHB-CT-2004-005246 "COMPUVAC"), the European Research Council (ERC Advanced Grant to FLC No. 233130 "HEPCENT"), and the Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS). MD was supported by a fellowship from the Region Rhone-Alpes.
###end p 177

